Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________

 


FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

pursuant to Section 13 or 15(d)

ofFor the Securities Exchange Act of 1934quarterly period ended September 30, 2022

 

 or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED December 31, 201For the transition period from7to.

 

 

000-15701

(Commission file number)

 


NATURAL ALTERNATIVES INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Delaware

84-1007839

(State of incorporation)

(IRS Employer Identification No.)

  

1535 Faraday DriveAve

Carlsbad, CaliforniaCA 92008

(760) 744-7340736-7700

(Address of principal executive offices)

(Registrant'sRegistrants telephone number)

 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock, $0.01 par value per share

NAII

Nasdaq Stock Market

 

Indicate by check mark whether Natural Alternatives International, Inc. (NAI)NAI (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that NAI was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

[X]     ☒  Yes   [_]     ☐  No

 

Indicate by check mark whether NAI has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that NAI was required to submit and post such files).

[X]    ☒  Yes     [  ]  No

 

Indicate by check mark whether NAI is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,, or an emerging growth company.

 

Large accelerated filer

Accelerated filer

Emerging Growth Company

      

Non-accelerated filer

Smaller reporting company

  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether NAI is a shell company (as defined in Rule 12b-2 of the Exchange Act).

[_]: ☐ Yes   [X] No

 

As of February 13, 2018, 7,429,020November 9, 2022, 6,061,533 shares of NAI's common stock were outstanding, net of 1,052,6573,129,873 treasury shares.

 

1

  

 

TABLE OF CONTENTS

 

Page

SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS

1

PART I

FINANCIAL INFORMATION

Item 1.

Financial Statements

Condensed Consolidated Balance Sheets

2

Condensed Consolidated Statements of Income and Comprehensive Income

3

Condensed Consolidated Statements of Stockholders’ Equity

4

Condensed Consolidated Statements of Cash Flows

4

5

Notes to Condensed Consolidated Financial Statements

5

6

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

15

17

Item 4.

Controls and Procedures

19

22

PART II

OTHER INFORMATION

23

Item 1.

Legal Proceedings

20

23

Item 1A.

Risk Factors

21

23

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

22

23

Item 3.

Defaults Upon Senior Securities

22

23

Item 5.

Other Information

22

23

Item 6.

Exhibits

23

24

SIGNATURES

24

25

 

 

  

SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS

 

Certain statements in this Quarterly Report,report, including information incorporated by reference, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect current views about future events and financial performance based on certain assumptions. They include opinions, forecasts, intentions, plans, goals, projections, guidance, expectations, beliefs, or other statements that are not statements of historical fact. Words such as “may,” “will,” “should,” “could,” “would,” “expects,“expect,“plans,“plan,“believes,“believe,“anticipates,“anticipate,“intends,“intend,“estimates,“estimate,“approximates,“approximate,“predicts,“predict,“forecasts,“forecast,“project,”, “future”, or “projects,”“likely”, or the negative or other variation of such words, and similar expressions may identify a statement as a forward-looking statement. Any statements that refer to projections of our future financial performance, our anticipated growth and trends in our business, our goals, strategies, focus and plans, and other characterizations of future events or circumstances, including statements expressing general optimism or pessimism about future operating results, are forward-looking statements. Forward-looking statements in this Quarterly Reportreport may include statements about:

 

 

future financial and operating results, including projections of net sales, revenue, income or loss, net income or loss per share, profit margins, expenditures, liquidity, the effect of changes in tax law and other financial items;

our ability to maintain or increase our patent and trademark licensing revenues;

our ability to develop market acceptance for and increase sales of new products, develop relationships with new customers and maintain or improve existing customer relationships;

 

the impact, of the Covid-19 Pandemic (“COVID-19”) and other external factors both within and outside of our control, on our business and results in operations including variations in our quarterly net sales, our employees, supply chain, vendors and customers;

future financial and operating results, including projections of net sales, revenue, income or loss, net income or loss per share, profit margins, expenditures, liquidity, and other financial items;

our ability to maintain or increase our patent and trademark licensing revenues;

our ability to attract and retain sufficient labor to successfully execute our business strategies and achieve our goals and objectives;

inventory levels, including the adequacy of quality raw material and other inventory levels to meet future customer demand, in particular assumptions regarding the impact of the COVID-19 pandemic;

our ability to price our products to achieve profit margin targets, especially in the current volatile raw material and labor environment;

our ability to protect our intellectual property;

future economic and political conditions, including implementation of new or increased tariffs;

 

our ability to improve operating efficiencies, manage costs and business risks, and improve or maintain profitability;

 

currency exchange rates and their effect on our results of operations including(including amounts that we may be reclassifiedreclassify as earnings,earnings), the availability of foreign exchange facilities, our ability to effectively hedge against foreign exchange risks and the extent to which we may seek to hedge against such risks;

 

future levels of our revenue concentration risk;

the outcome of currently pending litigation, regulatory and tax matters we may become involved in, the costs associated with such matters and the effect of such matters on our business and results of operationsoperations;

 

sources, availability and availabilityquality of raw materials, including the limited number of suppliers of beta-alanine and certain other raw materials; meeting our quality requirements;

 

inventories, including the adequacy of raw material and other inventory levels to meet future customer demand and the adequacy and intended use of our facilities;

 

potential manufacturing and distribution channels, product returns, and potential product recalls;recalls;

 

current or future customer orders;

 

the impact of external factors on our business and results of operations, fromespecially, for example, variations in quarterly net sales from seasonal and other external factors;

 

our ability to operate within the standards set by the U.S. Food and Drug Administration’sAdministration’s (FDA) Good Manufacturing Practices (GMP)(GMPs);

 

our ability to successfully expand our operations, including outside the United States (U.S.);

 

the adequacy of our financial reserves and allowances;

current and future economic and political conditions;

 

the sufficiency of our available cash, cash equivalents, and potential cash flows from our operations to fund our current working capital needs and capital expendituresexpenditure needs through the next 12 months;months and longer;

 

the impact of accounting pronouncements and our adoption of certain accounting guidance; and

 

other assumptions described in this reportReport underlying or relating to any forward-looking statements.

 

The forward-lookingForward-looking statements in this Quarterly Report speak only as of the date of this Quarterly Report based on information available to us at that time and caution should be taken not to place undue reliance on any such forward-looking statements. Forward-looking statements are subject to certain future events, risks, and uncertainties that are or may be outside of our control. When considering forward-looking statements, you should carefully review the risks, uncertainties and other cautionary statements in this Quarterly Report as they identify certain important factors that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These factors include, among others, the risks described under Item 1A of Part II and elsewhere in this QuarterlyI of our fiscal 2022 Annual Report, as well as in other reports and documents we have filed and will file with the United States Securities and Exchange Commission (SEC).

Unless the context requires otherwise, all references in this Quarterly Report to the “Company,” “NAI,” “we,” “our,” and “us” refer to Natural Alternatives International, Inc. and, as applicable, Natural Alternatives International Europe S.A. (NAIE).

 

1

 

PART I FINANCIAL INFORMATION

 

ITEM 1.FINANCIAL STATEMENTS

 

NATURAL ALTERNATIVES INTERNATIONAL, INC.Natural Alternatives International, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

 

 

December 31,

2017

  

June 30,

2017

 
 

(Unaudited)

      

September 30,

2022

  

June 30, 2022

 

Assets

         

(Unaudited)

   

Current assets:

         

Cash and cash equivalents

 $28,843  $27,843  $12,341  $21,833 

Accounts receivable - less allowance for doubtful accounts of $14 at December 31, 2017 and $18 at June 30, 2017

  12,895   8,410 

Notes receivable

  1,500    

Accounts receivable – less allowance for doubtful accounts of $3,359 at September 30, 2022 and $3,383 at June 30, 2022

 14,822  17,422 

Inventories, net

  17,879   13,729  39,990  32,475 

Income tax receivable

     261  445  67 

Forward contracts

 4,441  3,144 

Prepaids and other current assets

  1,585   1,456   2,365   1,805 

Total current assets

  62,702   51,699  74,404  76,746 

Property and equipment, net

  18,733   18,136  51,384  44,573 

Deferred income taxes

  2,443   2,002 

Operating lease right-of-use assets

 21,136  21,701 

Other noncurrent assets, net

  709   774   2,644   2,983 

Total assets

 $84,587  $72,611  $149,568  $146,003 
        

Liabilities and Stockholders’ Equity

            

Current liabilities:

         

Accounts payable

 $12,182  $5,116  $17,659  $16,185 

Accrued liabilities

  2,215   1,931  2,355  2,787 

Accrued compensation and employee benefits

  1,089   1,594  2,555  3,673 

Forward contract

  2,088   422 

Customer deposits

 108  140 

Income taxes payable

  1,636   1,207  335  174 

Forward contracts

 67   

Mortgage note payable, current portion

 305  302 

Line of credit

  3,400    

Total current liabilities

  19,210   10,270  26,784  23,261 
 

Long-term liability – operating leases

 21,144  22,047 

Long-term pension liability

  409   557  369  344 

Deferred rent

  551   537 

Forward contract, noncurrent

  609   99 

Income taxes payable, noncurrent

  2,950    

Deferred tax liability

 1,006  1,220 

Mortgage note payable, net of current portion

 9,422  9,493 

Income taxes payable, noncurrent

  987   1,118 

Total liabilities

  23,729   11,463   59,712   57,483 
        

Commitments and contingencies

        

Stockholders’ equity:

        

Commitments and contingencies (Notes E, F, and L)

       

Stockholders’ equity:

 

Preferred stock; $.01 par value; 500,000 shares authorized; none issued or outstanding

          

Common stock; $.01 par value; 20,000,000 shares authorized; issued and outstanding (net of treasury shares) 7,429,020 at December 31, 2017 and 6,937,018 at June 30, 2017

  84   79 

Common stock; $.01 par value; 20,000,000 shares authorized at September 30, 2022 and June 30, 2022, issued and outstanding (net of treasury shares) 6,082,816 at September 30, 2022 and 6,129,611 at June 30, 2022

 89  89 

Additional paid-in capital

  23,266   22,260  30,658  30,423 

Retained earnings

  45,904   45,788  78,714  77,661 

Treasury stock, at cost, 1,052,657 shares at December 31, 2017 and 1,044,659 June 30, 2017

  (6,160

)

  (6,074

)

Accumulated other comprehensive loss

  (2,236

)

  (905

)

Total stockholders’ equity

  60,858   61,148 

Total liabilities and stockholders’ equity

 $84,587  $72,611 

Treasury stock, at cost, 3,108,590 shares at September 30, 2022 and 3,061,795 at June 30, 2022

 (21,849

)

 (21,352

)

Accumulated other comprehensive income

  2,244   1,699 

Total stockholders’ equity

  89,856   88,520 

Total liabilities and stockholders’ equity

 $149,568  $146,003 

See accompanying notes to condensed consolidated financial statements.

 

2

 

Natural Alternatives International, Inc.

 

NATURAL ALTERNATIVES INTERNATIONAL, INC.

Condensed Consolidated Statements Ofof Income Andand Comprehensive Income

(In thousands, except share and per share data)

(Unaudited)

 

 

Three Months Ended

  

Six Months Ended

  

Three Months Ended

 
 

December 31,

  

December 31,

  

September 30,

 
 

2017

  

2016

  

2017

  

2016

  

2022

  

2021

 

Net sales

 $33,335  $30,559  $61,409  $64,626  $43,127  $38,340 

Cost of goods sold

  26,713   24,064   48,417   50,462   37,756   30,059 

Gross profit

  6,622   6,495   12,992   14,164  5,371  8,281 

Selling, general and administrative

  4,341   3,382   8,828   7,515   3,829   4,053 
                 

Income from operations

  2,281   3,113   4,164   6,649   1,542   4,228 
                 

Other income (expense):

                

Other expense:

 

Interest income

  304   133   554   249  4   

Foreign exchange (loss) gain

  (88

)

  262   (231

)

  203 

Interest expense

 (75

)

 (13

)

Foreign exchange loss

 (147

)

 (6

)

Other, net

  (14

)

  (8

)

  (13

)

  (15

)

  (6

)

  (7

)

Total other income

  202   387   310   437 

Total other expense

  (224

)

  (26

)

 

Income before income taxes

  2,483   3,500   4,474   7,086  1,318  4,202 

Provision for income taxes

  3,801   1,034   4,358   2,130   265   946 

Net (loss) income

 $(1,318

)

 $2,466  $116  $4,956 

Net income

 $1,053  $3,256 
                 

Unrealized (loss) gain resulting from change in fair value of derivative instruments, net of tax

  (197

)

  1,242   (1,331

)

  852 

Unrealized gain resulting from change in fair value of derivative instruments, net of tax

  545   954 
                 

Comprehensive (loss) income

 $(1,515

)

 $3,708  $(1,215

)

 $5,808 

Comprehensive income

 $1,598  $4,210 
                 

Net (loss) income per common share:

                

Net income per common share:

 

Basic

 $(0.20

)

 $0.38  $0.02  $0.76  $0.18  $0.52 

Diluted

 $(0.20

)

 $0.37  $0.02  $0.74  $0.18  $0.51 
                 

Weighted average common shares outstanding

                

Weighted average common shares outstanding:

 

Basic

  6,615,355   6,567,468   6,610,937   6,562,932  5,919,649  6,287,627 

Diluted

  6,615,355   6,683,356   6,836,567   6,665,159  5,943,446  6,351,345 

 

See accompanying notes to condensed consolidated financial statements.

 

3

 

Natural Alternatives International, Inc.

 

NATURAL ALTERNATIVES INTERNATIONAL, INC.

Condensed Consolidated Statements Of Cash Flowsof Stockholders’ Equity

Three-Month Period Ended September 30, 2022 and 2021

(InDollars in thousands)

(Unaudited)

 

  

Six Months Ended

 
  

December 31,

 
  

2017

  

2016

 
         

Cash flows from operating activities

        

Net income

 $116  $4,956 

Adjustments to reconcile net income to net cash provided by operating activities:

        

Depreciation and amortization

  1,479   1,059 

Deferred income taxes

  306    

Non-cash sales discount

  408    

Non-cash compensation

  603   506 

Pension expense, net of contributions

  (148

)

  100 

Gain on disposal of assets

  (2

)

  (23

)

Changes in operating assets and liabilities:

        

Accounts receivable, net

  (4,485

)

  3,379 

Inventories, net

  (4,150

)

  3,701 

Prepaids and other assets

  (64

)

  42 

Accounts payable and accrued liabilities

  6,942   (6,721

)

Accrued compensation and employee benefits

  (505

)

  (1,726

)

Forward contracts

  520   (491)

Income taxes

  3,640   255 

Net cash provided by operating activities

  4,660   5,037 
         

Cash flows from investing activities

        

Purchases of property and equipment

  (2,095

)

  (3,362

)

Proceeds from sale of property and equipment

  21   24 

Issuance of notes receivable

  (1,500

)

   

Net cash used in investing activities

  (3,574

)

  (3,338

)

         

Cash flows from financing activities

        

Repurchase of common stock

  (86

)

  (84

)

Net cash used in financing activities

  (86

)

  (84

)

         

Net increase in cash and cash equivalents

  1,000   1,615 

Cash and cash equivalents at beginning of period

  27,843   19,747 

Cash and cash equivalents at end of period

 $28,843  $21,362 
         

Supplemental disclosures of cash flow information

        

Cash paid during the period for:

        

Interest

 $  $ 

Taxes

 $422  $1,897 

Disclosure of non-cash activities:

        

Change in unrealized (loss) gain resulting from change in fair value of derivative instruments, net of tax

 $(1,331

)

 $852 
  

Common Stock

  

Additional
Paid-in

  

Retained

  

Treasury Stock

  

Accumulated
Other
Comprehensive

     
  

Shares

  

Amount

  

Capital

  

Earnings

  

Shares

  

Amount

  

Income (Loss)

  

Total

 

Balance, June 30, 2022

  9,191,406  $89  $30,423  $77,661   3,061,795  $(21,352

)

 $1,699  $88,520 

Compensation expense related to stock compensation plans

        235               235 

Repurchase of common stock

              46,795   (497

)

     (497)

Unrealized gain resulting from change in fair value of derivative instruments, net of tax

                    545   545 

Net income

           1,053            1,053 

Balance, September 30, 2022

  9,191,406  $89  $30,658  $78,714   3,108,590  $(21,849

)

 $2,244  $89,856 
                                 

Balance, June 30, 2021

  9,004,365  $88  $29,456  $66,949   2,567,797  $(15,849

)

 $(561

)

 $80,083 

Compensation expense related to stock compensation plans

        222               222 

Repurchase of common stock

              692   (10

)

     (10)

Forfeiture of restricted stock

              16,332          

Unrealized gain resulting from change in fair value of derivative instruments, net of tax

                    954   954 

Net income

           3,256            3,256 

Balance, September 30, 2021

  9,004,365  $88  $29,678  $70,205   2,584,821  $(15,859

)

 $393  $84,505 

See accompanying notes to condensed consolidated financial statements.

 

4

Natural Alternatives International, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

  

Three Months Ended

September 30,

 
  

2022

  

2021

 

Cash flows from operating activities

        

Net income

 $1,053  $3,256 

Adjustments to reconcile net income to net cash used in operating activities:

        

(Recovery of) provision for uncollectible accounts receivable

  (24

)

  67 

Depreciation and amortization

  956   1,092 

Non-cash compensation

  235   222 

Non-cash lease expenses

  454   725 

Pension expense, net of contributions

  25   9 

Gain on disposal of assets

     (6

)

Changes in operating assets and liabilities:

        

Accounts receivable

  2,625   (2,366

)

Inventories, net

  (7,515

)

  (4,703

)

Prepaids and other assets

  (719

)

  (101

)

Accounts payable and accrued liabilities

  1,010   343 

Forward contracts

  (33

)

  (1,126

)

Accrued compensation and employee benefits

  (1,119

)

  (1,894

)

Operating lease liabilities

  (792

)

  (804

)

Income taxes

  (716

)

  1,510 

Net cash used in operating activities

  (4,560

)

  (3,776

)

         

Cash flows from investing activities

        

Proceeds from sale of property and equipment

     25 

Purchases of property and equipment

  (7,767

)

  (18,344

)

Net cash used in investing activities

  (7,767

)

  (18,319

)

         

Cash flows from financing activities

        

Net borrowings on line of credit

  3,400    

(Payments) borrowings on long-term debt

  (68

)

  10,000 

Repurchase of common stock

  (497

)

  (10

)

Net cash provided by financing activities

  2,835   9,990 
         

Net decrease in cash and cash equivalents

  (9,492

)

  (12,105

)

Cash and cash equivalents at beginning of period

  21,833   32,133 

Cash and cash equivalents at end of period

 $12,341  $20,028 
         

Supplemental disclosures of cash flow information

        

Cash paid during the period for:

        

Interest

 $75  $13 

Taxes

 $827  $303 

See accompanying notes to condensed consolidated financial statements.

5

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

 

A. Basis of Presentation and Summary of Significant Accounting Policies

 

The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and with applicable rules and regulations. CertainPursuant to such rules and regulations, certain information and footnotenote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations.omitted. In management’smanagement’s opinion, all adjustments necessary for a fair presentation of the financial position, results of operations, stockholders’ equity, and cash flows have been included and are of a normal, recurring nature. The results of operations for the three and sixmonths ended December 31, 2017September 30, 2022 are not necessarily indicative of the operating results for the full fiscal year or for any future periods.

 

You should read the financial statements and these notes, which notes are an integral part of the financial statements, together with our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (2017 (20172022 Annual Report”). The accounting policies used to prepare the financial statements included in this Quarterly Report are the same as thosepolicies described in the notes to the consolidated financial statements in our 20172022 Annual Report unless otherwise noted below.

 

RecentRecently Adopted Accounting Pronouncements

 

InWe did March 2016, not adopt any accounting pronouncements during the FASBthree months ended September 30, 2022.

Recently Issued Accounting and Regulatory Pronouncements

Other recently issued Accounting Standards Updateaccounting pronouncements are No.not 2016-02, Leases (Topic 842) (ASU 2016-02), which amends existing standards for leasesdiscussed in this Report as such pronouncements did not have, and are not believed by management to increase transparency and comparability among organizations by requiring recognition of lease assets and liabilities on the balance sheet and requiring disclosure of key information about such arrangements. ASU 2016-02 will be effective for us beginning in our first quarter of fiscal 2020. Early adoption is permitted. We are currently evaluating thehave, a material impact of adopting the new standard on our consolidatedpresent or future financial statements and the timing and presentation of our adoption.statements.

 

In April 2016, the FASB issued Accounting Standards Update No.2016-10, Revenue from Contracts with Customers (Topic 606)(ASU 2016-10), which amends and adds clarity to certain aspects of the guidance set forth in the upcoming revenue standard (ASU 2014-09) related to identifying performance obligations and licensing. In May 2016, the FASB issued Accounting Standards Update No.2016-11, Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815) (ASU 2016-11), which amends and rescinds certain revenue recognition guidance previously released within ASU 2014-09. In May 2016 the FASB issued Accounting Standards Update No.2016-12, Revenue from Contracts with Customers (Topic 606) (ASU 2016-12), which provides narrow scope improvements and practical expedients related to ASU 2014-09. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible that more judgment and estimates may be required within the revenue recognition process than is required under present U.S. GAAP. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price, and allocating the transaction price to each separate performance obligation. The new standard also requires additional disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments. All of these new standards will be effective for us concurrently with ASU 2014-09, beginning in our first quarter of fiscal 2019. Currently, we do not expect our annual revenue to be materially different under Topic 606. The most significant change will be to our quarterly and annual financial statement disclosures.  We are continuing to evaluate the impact of adopting the new standard.

In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The ASU is intended to improve and simplify accounting rules around hedge accounting and improve the disclosures of hedging arrangements. We are currently evaluating the impact of adopting the new standard on our consolidated financial statements. ASU 2017-12 will be effective for us beginning in our first quarter of fiscal 2020.

On December 22, 2017, the SEC issued guidance under Staff Accounting Bulletin No.118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) directing taxpayers to consider the impact of the U.S. legislation as “provisional” when it does not have the necessary information available, prepared or analyzed (including computations) in reasonable detail to complete its accounting for the change in tax law. In accordance with SAB 118, the our estimated income tax is considered provisional and is expected to be finalized by the end of our fiscal year.

5

Net Income per Common Share

 

We compute net income per common share using the weighted average number of common shares outstanding during the period, and diluted net income per common share using the additional dilutive effect of all dilutive securities. The dilutive impact of stock options and unvested restricted shares account for the additional weighted average shares of common stock outstanding for our diluted net income per common share computation. We calculated basic and diluted net income per common share as follows (in thousands, except per share data):

 

 

Three Months Ended

  

Six Months Ended

  

Three Months Ended

 
 

December 31,

  

December 31,

  

September 30,

 
 

2017

  

2016

  

2017

  

2016

  

2022

  

2021

 

Numerator

                        

Net (loss) income

 $(1,318

)

 $2,466  $116  $4,956 

Net income

 $1,053  $3,256 
                     

Denominator

                        

Basic weighted average common shares outstanding

  6,615   6,567   6,611   6,563  5,920  6,288 

Dilutive effect of stock options

     116   226   102 

Dilutive effect of stock options and restricted stock

  23   63 

Diluted weighted average common shares outstanding

  6,615   6,683   6,837   6,665   5,943   6,351 
                     

Basic net (loss) income per common share

 $(0.20

)

 $0.38  $0.02  $0.76 

Basic net income per common share

 $0.18  $0.52 
                     

Diluted net (loss) income per common share

 $(0.20

)

 $0.37  $0.02  $0.74 

Diluted net income per common share

 $0.18  $0.51 

 

6

In periods where we have a net loss, stock options andWe excluded 50,377 shares of restricted stock are excluded from our calculation of diluted net income (loss) per common share, as their inclusion would have an antdilutive effect. We excludedand no shares related to stock options totaling 135,000 and shares related to restricted stock totaling 813,665 for the three months ended December 31, 2017.September 30, 2022, as their impact would have been anti-dilutive. We did Nonot shares related toexclude any stock options or restrictedrestrictive stock were excludedshares for the sixthree months ended December 31, 2017September 30, 2021, or theas threenone and six months ended December 31, 2016.would have had an anti-dilutive impact.

 

Revenue Recognition

 

To recognizeWe record revenue based on a fourfive basic criteria must be met: -step model which includes: (1) there is evidence that an arrangement identifying a contract with a buyer exists; customer; (2) delivery has occurred; identifying the performance obligations in the contract; (3) determining the fee is fixed or determinable; and transaction price; (4) collectabilityallocating the transaction price among the performance obligations; and (5) recognizing revenue as each of the various performance obligations are satisfied.

Revenue is reasonably assured. Revenuemeasured as the net amount of consideration expected to be received in exchange for fulfilling one or more performance obligations. We identify purchase orders from sales transactions wherecustomers as contracts. The amount of consideration expected to be received and revenue recognized includes estimates of variable consideration, including estimates for early payment discounts and volume rebates. Such estimates are calculated using historical averages adjusted for any expected changes due to current business conditions and experience. We review and update these estimates at the buyer hasend of each reporting period and the rightimpact of any adjustments is recognized in the period the adjustments are identified. In assessing whether collection of consideration from a customer is probable, we consider both the customer's ability and intent to returnpay that amount of consideration when it is due. Payment of invoices is due as specified in the productunderlying customer agreement, which is typically 30 days from the invoice date. Invoices are generally issued on the date of transfer of control of the products ordered to the customer.

Revenue is recognized at the point in time that each of sale only if (a)our performance obligations is fulfilled, and control of the seller’s priceordered products is transferred to the buyercustomer. This transfer occurs when the product is substantially fixedshipped, or determinable atin some cases, when the date of sale; (b) the buyer has paid the seller, or the buyerproduct is obligated to pay the seller and the obligation is not contingent on resale of the product; (c) the buyer’s obligationdelivered to the seller would not be changed in the event of theft or physical destruction or damage of the product; (d) the buyer acquiring the product for resale has economic substance apart from that provided by the seller; (e) the seller does not have significant obligations for future performance to directly bring about resale of the product by the buyer; and (f) the amount of future returns can be reasonably estimated. customer.

We recognize revenue upon determination that all criteria for revenue recognition have been met. The criteria are usually met at the time title passesin certain circumstances before delivery to the customer which usually occurs upon shipment. Revenue from shipments where title passes upon completionhas occurred (commonly referred to as bill-and-hold transactions). Products sold under bill-and-hold arrangements are recorded as revenue when risk of delivery is deferred until the shipmentownership has been delivered.transferred to the customer, but the product has not shipped due to a substantive reason, typically at the customer’s request. The product must be separately identified as belonging to the customer, ready for physical transfer to the customer, and we cannot have the ability to redirect the product to another customer.

 

6

Contract liabilities and revenue recognized were as follows (in thousands):

  

June 30, 2022

  

Additions

  

Revenue

Recognized

  

September

30, 2022

 

Contract Liabilities (Customer Deposits)

 $140   108  $(140)  108 

  

June 30, 2021

  

Additions

  

Revenue

Recognized

  

September

30, 2021

 

Contract Liabilities (Customer Deposits)

 $1,721   1,941  $(1,721)  1,941 

 

We record reductions to gross revenue for estimated returns of private-label contract manufacturing products and beta-alanine raw material sales. The estimated returns are based on the trailing six months of private-label contract manufacturing gross sales and our historical experience for both private-label contract manufacturing and beta-alanine raw material sales returns. However, the estimate for product returns does not reflect the impact of a potential large product recall resulting from product nonconformance or other factors as such events are not predictable nor is the related economic impact estimable.

On August 7, 2017, we entered into three agreements (“Agreements”), with The Juice Plus+ Company LLC (“Juice Plus+”). The Agreements are an Exclusive Manufacturing Agreement, a Restricted Stock Award Agreement, and an Irrevocable Proxy. Pursuant to the Exclusive Manufacturing Agreement, Juice Plus+ has granted us exclusive rights to manufacture and supply them with certain of their products within 24 countries where Juice Plus+ currently sells those products. Pursuant to the Restricted Stock Award Agreement, NAI has granted 500,000 shares of NAI common stock to Juice Plus+, (the “Shares”), and Juice Plus+ has agreed the Shares are subjectprovide early payment discounts to certain restrictions and riskcustomers. Based on historical payment trends, we expect that these customers will take advantage of forfeiture. Pursuant to the Irrevocable Proxy, Juice Plus+ also has granted to the NAI Boardthese early payment discounts. The cost of Directors Juice Plus+’s right to vote the Shares that remain subject to the associated risk of forfeiture. The Agreements each are for a term of 5 years, and each may be terminated by either party only upon the occurrence of specified events. The expense associated with the shares granted to Juice Plus+these discounts is recordedreported as a reduction to revenue. the transaction price. If the actual discounts differ from those estimated, the difference is also reported as a change in the transaction price. We recordedrequire prepayment from certain customers. We record any payments received in advance of contracts fulfillment as a contract liability and classified as customer deposits on the consolidated balance sheet.

Except for product defects, no right of return exists on the sale of our products. We estimate returns based on historical experience and recognize a returns liability for any estimated returns. As of $245,000September 30, 2022, we have no of expense during the three months ended December 31, 2017 and $408,000 during the six months ended December 31, 2017.estimated returns liability.

 

We currently own certain U.S. patents, and patent applications, and each patent’s corresponding foreign patents and patent applications. All of these patents and patent rights relate to the ingredient known as beta-alanine marketed and which we market and sellsold under our CarnoSyn® and SR CarnoSyn® trade names. We recorded beta-alanine raw material sales and royalty and licensing income as a component of revenue in the amount of $4.0$1.4 million during the three months ended December 31, 2017 and $9.8 million during the six months ended December 31, 2017.September 30, 2022. We similarly recorded $6.7$4.7 million during the three months ended December 31, 2016 and $13.4 million during the six months ended December 31, 2016.September 30, 2021. These royalty income and raw material sale amounts resulted in royalty expense paid to the original patent holders from whom NAI acquired its patents and patent rights. We recognized royalty expense as a component of cost of goods sold in the amount of $160,000$27,000 during the three months ended December 31, 2017 and $444,000 during the six months ended December 31, 2017.September 30, 2022. We recognized $250,000recorded $200,000 during the three months ended December 31, 2016 September 30, 2021.and $566,000 during the six months ended December 31, 2016.

 

Notes Receivable

On

September 30, 2017, 7we accepted a 12-month note from Kaged Muscle, LLC (“Kaged Muscle”), one

Stock-Based Compensation

 

We have anThe Board of Directors approved our current omnibus equity incentive plan that was approved by our Board of Directorsbecame effective as of OctoberJanuary 1, 2021 (the 15,“2020 2009 andPlan”), which was approved by our stockholders at the Annual Meeting of Stockholders held on NovemberDecember 4, 2020. 30,2009.Under the plan,2020 Plan, we may grant nonqualified and incentive stock options, restricted stock grants, restricted stock units, stock appreciation rights, and other stock-based awards to employees, non-employee directors and consultants.

We estimate the fair value of stock option awards at the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. Option valuation models require the input of highly subjective assumptions. Black-Scholes uses assumptions related to volatility, the risk-free interest rate, the dividend yield (which we assume to be zero, as to date we have not paid any cash dividends) and employee exercise behavior. Expected volatilities used in the model are based on the historical volatility of our stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect on the date of grant. The expected life of stock option grants is derived from historical experience. The fair value of restricted stock shares granted is based on the market price of our common stock on the date of grant. We amortize the estimated fair value of our stock awards to expense over the related vesting periods.

7

 

We did not grant any options during the three month or six month periods ended December 31, 2017September 30, 2022 orand 2016.September 30, 2021. All remaining outstanding stock options are fully vested. No options were exercised during the three month or six month periods ended December 31, 2017September 30, 2022 orand 2016.September 30, 2021. There were no forfeitures during the three months ended December 31, 2017. During the six months ended December 31, 2017 5,000 options were forfeited. There were nooption forfeitures during the three month or six month periods ended December 31, 2016.September 30, 2022 and September 30, 2021. As of September 30, 2022, we did not have any stock options outstanding.

 

We did not grant any restricted stock shares to employees during the three or six months ended December 31, 2017, or the three months ended December 31, 2016.September 30, 2022 We grantedor 10,000September 30, 2021. No restricted stock shares to a new member of managementwere forfeited during the sixthree months ended December 31, 2016.September 30, 2022. During the three months ended September 30, 2021, 16,332 restricted stock shares were forfeited. Our net income included stock-based compensation expense in connection with prior restricted stock grants of approximately $0.2 million for the three months ended September 30, 2022. Our net income included stock based compensation expense in connection with the vesting of prior restricted stock grants of approximately $302,000$0.2 million for the three months ended December 31, 2017,September 30, 2021.

Deferred Compensation Plan

Effective July 16, 2020, the Board of Directors approved and adopted a Non-Qualified Incentive Plan (the “Incentive Plan”). Pursuant to the Incentive Plan, the Human Resources Committee and the Board of Directors may make deferred cash payments or other cash awards (“Awards”) to directors, officers, employees and eligible consultants of NAI, (“Participants”). These Awards are made subject to conditions precedent that must be met before NAI is obligated to make the payment. The purpose of the Incentive Plan is to enhance the long-term stockholder value of NAI by providing the Human Resources Committee and the Board of Directors the ability to make deferred cash payments or other cash awards to encourage Participants to serve NAI or to remain in the service of NAI, or to assist NAI to achieve results determined by the Human Resources Committee or the Board of Directors to be in NAI's best interest.

The Incentive Plan authorizes the Human Resources Committee or the Board of Directors to grant to, and administer, unsecured and deferred cash Awards to Participants and to subject each Award to whatever conditions are determined appropriate by the Human Resources Committee or the Board of Directors. The terms of each Award, including the amount and any conditions that must be met to be entitled to payment of the Award are set forth in an Award Agreement between each Participant and NAI. The Incentive Plan provides the Board of Directors with the discretion to set aside assets to fund the Incentive Plan although that has not been done to date.

No deferred cash awards were granted during the three months ended September 30, 2022 and $603,000September 30, 2021. No for the six months ended December 31, 2017. Our net income included stock based compensation expense of approximately $256,000 fordeferred cash awards were forfeited during the three months ended December 31, 2016,September 30, 2022. and $506,000 forDuring the sixthree months ended December 31, 2016.September 30, 2021, awards totaling $191,000 were forfeited.

 

Fair Value of Financial Instruments

 

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in the principal or most advantageous marketExcept for the asset or liability in an orderly transaction between market participants at the measurement date. We use a three-level hierarchy for inputs used in measuring fair value that maximizes the use of observable inputscash and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available under the circumstances.  

The fair value hierarchy is broken down into three levels based on the source of inputs. In general, fair values determined by Level 1 inputs use quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access. We classify cash, cash equivalents, and marketable securities balances as Level 1 assets. Fair values determined by Level 2 inputs are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable or can be corroborated, either directly or indirectly by observable market data. Level 3 inputs are unobservable inputs for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. These include certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

As of DecSeptember 30, 2022, ember 31,2017and June 30, 2017,2022, we did not have any financial assets or liabilities classified as Level 11. except for cash and cash equivalents, and assets related to our pension plan. We classify derivative forward exchange and interest rate swap contracts as Level 2 assets.assets and liabilities. The fair values were determined by obtaining pricing from our bank and corroborating those values with a third party bank or pricing service.

8

Fair value of our forward exchange contractsderivative instruments classified as Level 2 assets and liabilities consisted of December 31, 2017 wasthe following (in thousands):

  

September 30,

2022

  

June 30,

2022

 

Euro Forward Contract– Current Assets

 $4,441  $3,144 

Swiss Franc Forward Contract – Current Assets

     109 

Total Derivative Contracts – Current Assets

  4,441   3,253 
         

Interest Swap – Other noncurrent Assets

  627   453 

Euro Forward Contract– Other noncurrent Assets

     561 

Total Derivative Contracts – Other noncurrent Assets

  627   1,014 
         

Swiss Franc Forward Contract – Current Liabilities

  (67

)

   

Total Derivative Contracts – Current Liabilities

  (67

)

   
         

Fair Value Net Asset – all Derivative Contracts

 $5,001  $4,267 

We also classify any outstanding line of credit and term loan balance as a net liability ofLevel $2.72 million. The fair value of our forward exchange contracts as of June 30, 2017 was a net liability of $521,000.liability. As of December 31, 2017September 30, 2022, and June 30, 20172022, we did not have any financial assets or liabilities classified as Level 3. We did not transfer any assets or liabilities between Levelsthese levels during fiscal 20172022 or the sixthree months ended December 31, 2017.September 30, 2022. 

  

Concentrations of Credit Risk

Financial instruments that subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. We place our cash and cash equivalents with highly rated financial institutions. Credit risk with respect to receivables is concentrated with our three largest customers, whose receivable balances collectively represented 76.1% of gross accounts receivable at December 31,2017 and 65.6% at June 30,2017. Additionally, amounts due related to our beta-alanine raw material sales were 15.6% of gross accounts receivable at December 31, 2017, and 21.3% of gross accounts receivable at June 30, 2017. Concentrations of credit risk related to the remaining accounts receivable balances are limited due to the number of customers comprising our remaining customer base.

 

B. Inventories, net

 

Inventories, net consisted of the following (in thousands):

 

 

December 31,

2017

  

June 30, 2017

  

September 30,

2022

  

June 30,

2022

 

Raw materials

 $12,623  $9,469  $31,752  $28,196 

Work in progress

  3,061   1,312  5,736  1,948 

Finished goods

  2,597   3,562  3,086  2,842 

Reserves

  (402

)

  (614

)

Inventories, net

 $17,879  $13,729 

Reserve

  (584

)

  (511

)

 $39,990  $32,475 

  

8

C. Property and Equipment

 

Property and equipment consisted of the following (in thousands):

 

 

Depreciable

Life In Years

  

December 31,

2017

  

June 30,

2017

 
             

Depreciable Life

In Years

  

September 30,

2022

  

June 30,

2022

 

Land

  N/A   $1,200  $1,200 

NA

  $7,645  $7,645 

Building and building improvements

 739   3,715   3,706 7-39  22,617  17,415 

Machinery and equipment

 312   25,499   24,194 3-12  42,301  40,131 

Office equipment and furniture

 35   4,350   3,954 3-5  5,986  5,970 

Vehicles

  3    209   209  3   211  211 

Leasehold improvements

 115   17,032   17,038 1-15   22,005   21,626 

Total property and equipment

       52,005   50,301      100,765  92,998 

Less: accumulated depreciation and amortization

       (33,272)  (32,165)      (49,381

)

  (48,425

)

Property and equipment, net

      $18,733  $18,136      $51,384  $44,573 

 

Depreciation expense was approximately $1.0 million for the three month period ended September 30, 2022 and $1.1 million for the three month period ended September 30, 2021.

9

 

D. Other Comprehensive Income (Loss) Income

 

OtherOther comprehensive income (loss) income (“OCL”OCI” and “OCI”“OCL”) consisted of the following during the three and sixmonths ended December 31, 2017September 30, 2022 and December 31, 2016September 30, 2021 (in thousands):

  

Three Months Ended

     
  

September 30, 2022

     
  

 

  

Unrealized

  

Unrealized

     
  Defined  Gains  Gains     
  

Benefit

  

(Losses) on

  

(Losses) on

     
  

Pension

  

Cash Flow

  

Swap

     
  

Plan

  

Hedges

  

Derivative

  

Total

 

Beginning Balance

 $(444

)

 $1,795  $348  $1,699 

OCI/OCL before reclassifications

     1,788   174   1,962 

Amounts reclassified from OCI to Sales

     (1,262)     (1,262

)

Tax effect of OCI activity

     (118

)

  (37

)

  (155

)

Net current period OCI/OCL

     408   137   545 
                 

Ending Balance

 $(444

)

 $2,203  $485  $2,244 

   Three Months Ended     
   September 30, 2021     
      Unrealized  Unrealized     
  Defined  Gains  Gains     
  Benefit  (Losses) on  (Losses) on     
  Pension  Cash Flow  Swap     
  Plan  Hedges  Derivative  Total 

Beginning Balance

 $(538

)

 $(23

)

 $  $(561)

OCI/OCL before reclassifications

     1,389      1,389 

Amounts reclassified from OCI to Sales

     (146)     (146

)

Tax effect of OCI activity

     (289

)

     (289

)

Net current period OCI/OCL

     954      954 
                 

Ending Balance

 $(538

)

 $931  $   393 

E. Leases

We currently lease our Vista, CA and Lugano, Switzerland product manufacturing and support facilities.

Leases are classified as operating leases. Substantially all our operating leases are comprised of payments for the use of manufacturing and office space. We have no leases classified as finance leases. As of September 30, 2022, the weighted average remaining lease term for our operating leases was 6.1 years and the weighted average discount rate for our operating leases was 4.13%. As of June 30, 2022, the weighted average remaining lease term for our operating leases was 6.3 years and the weighted average discount rate was 4.12%.

 

  

Three Months Ended

  

Six Months Ended

 
  

December 31, 2017

  

December 31, 2017

 
      

Unrealized

          

Unrealized

     
  

Defined

  

Gains

      

Defined

  

Gains

     
  

Benefit

  

(Losses) on

      

Benefit

  

(Losses) on

     
  

Pension

  

Cash Flow

      

Pension

  

Cash Flow

     
  

Plan

  

Hedges

  

Total

  

Plan

  

Hedges

  

Total

 

Beginning Balance

 $(491

)

 $(1,548

)

 $(2,039

)

 $(491

)

 $(414

)

 $(905

)

OCI/OCL before reclassifications

  -   (490

)

  (490

)

  -   (2,443

)

  (2,443

)

Amounts reclassified from OCI

  -   187   187   -   365   365 

Tax effect of OCI activity

  -   106   106   -   747   747 

Net current period OCI/OCL

  -   (197

)

  (197

)

  -   (1,331

)

  (1,331

)

Ending Balance

 $(491

)

 $(1,745

)

 $(2,236

)

 $(491

)

 $(1,745

)

 $(2,236

)

  

Three Months Ended

  

Six Months Ended

 
  

December 31, 2016

  

December 31, 2016

 
      

Unrealized

          

Unrealized

     
  

Defined

  

Gains

      

Defined

  

Gains

     
  

Benefit

  

(Losses) on

      

Benefit

  

(Losses) on

     
  

Pension

  

Cash Flow

      

Pension

  

Cash Flow

     
  

Plan

  

Hedges

  

Total

  

Plan

  

Hedges

  

Total

 

Beginning Balance

 $(775

)

 $(295

)

 $(1,070

)

 $(775

)

 $95  $(680

)

OCI/OCL before reclassifications

  -   2,287   2,287   -   1,834   1,834 

Amounts reclassified from OCI

  -   (343

)

  (343

)

  -   (501

)

  (501

)

Tax effect of OCI activity

  -   (702

)

  (702

)

  -   (481

)

  (481

)

Net current period OCI/OCL

  -   1,242   1,242   -   852   852 

Ending Balance

 $(775

)

 $947  $172  $(775

)

 $947  $172 

910

Other information related to leases as of September 30, 2022, was as follows (in thousands):

 

Supplemental Cash Flows Information

 

Three Months Ended

September 30, 2022

  

Three Months Ended

September 30, 2021

 

Cash paid for amounts included in the measurement of operating lease liabilities

 $811  $811 

Operating lease liabilities arising from obtaining Right of Use Assets for new leases

      

 

E.F. Debt

 

We haveOn May 24, 2021, we entered into a Credit Agreementnew credit facility with Wells Fargo Bank, N.A.N.A (“Wells Fargo”) to extend the maturity for our working line of credit from November 1, 2022 to May 24, 2024. This new credit facility provides total lending capacity of up to $20.0 million and allows us to use the credit facility for working capital as well as potential acquisitions. On August 18, 2021, we entered into an amendment of our credit facility with Wells Fargo. The amended credit facility added a $10.0 million term loan to the existing $20.0 million credit facility, and permitted us to use the $10.0 million term loan as part of the $17.5 million purchase consideration for the acquisition of our new manufacturing and warehouse property in Carlsbad, California. The amended credit agreement also increased the allowed capital expenditures from $10.0 million to $15.0 million for fiscal 2022, (exclusive of the amount paid for the acquisition of the new Carlsbad property noted above). In addition, the new credit notes now reflect a change in the interest rate reference from LIBOR to Secured Overnight Financing Rate (SOFR). The Credit Agreement provides uswas amended and a new Revolving Line of Credit Note, and Security Agreement were entered into. A Term Note and real property security documents were added to secure the Term Note by the new Carlsbad property. Additionally, we entered into a second amendment to our credit facility with a credit line of up to $10.0 million and maturesWells Fargo on February 1, 2020.8, 2022 The line of creditthat was effective mayJanuary 31, 2022 be usedand modified the annual limit imposed upon our ability to finance working capital requirements. Onrepurchase stock and issue dividends. This amendment increased this limit from $5.0 million annually to $7.0 million annually. Effective September 29, 2017,19, 2022, we executed anentered into a third amendment to the Credit Agreement, which now allows us to make loans or advances toour credit facility with Wells Fargo. The third partiesamendment extends the maturity date from notMay 24, 2024 exceeding $1.5 million. We executed this amendment in order to issue a note receivable of $1.5May 23, 2025 and also increased the allowed capital expenditures from $7.5 million to a customer. There is$25.0 million for the fiscal year ending noJune 30, 2023. commitment fee under this agreement. There are no amounts currently drawn under the line of credit.

 

11

Under the terms of the Credit Agreement, borrowings are subject to eligibility requirements including maintaining (i) a ratio of total liabilities to tangible net worth of not greater than 1.251.50 to 1.0 at any time; and (ii) a ratio of total current assets to total current liabilities of not less than 1.75 to 1.0 at each fiscal quarter end (iii) net income after taxes not less than $1.00, determined on a trailing four quarter basis with notwo consecutive quarterly losses, determined as of each quarter end and (iv) a rolling 4-quarter fixed charge coverage ratio not less than 1.25 to 1.0 as of each fiscal quarter end. The credit agreement also includes a limitation on the amount of capital expenditures that can be made in a given fiscal year, with such limitation set at $25.0 million for our fiscal year ending June 30, 2023 and $7.5 million for all fiscal years thereafter. Any amounts outstanding under the line of credit will bear interest at a fixed or fluctuating interest rate as elected by NAIus from time to time; provided, however, that if the outstanding principal amount is less than $100,000$100,000 such amount shall bear interest at the then applicable fluctuating rate of interest. If elected, the fluctuating rate per annum would be equal to 1.25%1.29% above the daily one month LIBORsimple SOFR rate as in effect from time to time. If a fixed rate is elected, it would equal a per annum rate of 1.25%1.29% above the LIBORSOFR rolling 30-day average rate in effect on the first day of the applicable fixed rate term. Any amounts outstanding under the line of credit must be paid in full on or before the maturity date. Amounts outstanding that are subject to a fluctuating interest rate may be prepaid at any time without penalty. Amounts outstanding that are subject to a fixed interest rate may be prepaid at any time in minimum amounts of $100,000,$100,000, subject to a prepayment fee equal to the sum of the discounted monthly differences between payment under a fixed rate versus payment under the variable rate for each month from the month of prepayment through the month in which the then applicable fixed rate term matures. There is an unused commitment fee of 0.125% required as part of the line of credit.

The Term Note used as part of the purchase consideration of our new manufacturing and warehouse property in Carlsbad California referenced above, is for the original principal amount of $10.0 million, and is a seven year term note with payments fully amortized based on a twenty five year assumed term. Installment payments under this loan commenced October 1, 2021 and continue through August 1, 2028 with a final installment consisting of all remaining amounts due to be paid in full on September 1, 2028. Amounts outstanding on this note during the term of the agreement will bear interest equal to 1.8% above the SOFR rolling 30-day average. In connection with our term loan, we entered into an interest rate swap with Wells Fargo that effectively fixes our interest rate on our term loan at 2.4% for the firstthree years of the term of the note.

 

Our obligations under the Credit Agreement are secured by our accounts receivable and other rights to payment, general intangibles, inventory, equipment and fixtures. We also have credit approval with Wells Fargo Bank, which allows us to hedge foreign currency exposures up to 30 months in the future. We also have credit approval with Bank of America which allows us to hedge foreign currency exposures up to 24 months in the future.

 

On December 31, 2017September 30, 2022, , we were in compliance with all of the financial and other covenants required under the Amended Credit Agreement.

 

We also have a foreign exchangeAs of September 30, 2022, we had $3.4 million outstanding on our credit facility and $16.6 million available for borrowing under our credit facility with Wells Fargo Bank, N.A. in effect until January 31, 2019, and with Bank of America, N.A. in effect until August 15, 2019.Bank.

 

We did not use our working capital line of credit nor did we have any long-term debt outstanding during the six months ended December 31, 2017. As of December 31, 2017,September 30, 2022, we had $10.0$9.7 million availableoutstanding under our credit facilities.the Term Note used in the purchase of the warehouse in August 2021.

  

 

F.G. Economic Dependency

 

We had substantial net sales to certain customers during the periods shown in the following table. The loss of any of these customers, or a significant decline in (i) sales to these customers, (ii) the growth rate of sales to these customers, or in(iii) these customerscustomers’ ability to make payments when due, each individually could have a material adverse impact on our net sales and net income. Net sales to any one customer representing 10% or more of the respective period's consolidated net sales were as follows (in thousands):

  

Three Months Ended

September 30,

 
  

2022

  

2021

 
         

Customer 1

 $15,152  $13,296 

Customer 2

  15,005   4,349 

Customer 3

  6,328   7,386 

Customer 4

 

(a)

   4,327 
  $36,485  $29,358 

(a)

Sales were less than 10% of the respective period’s total net sales.

Accounts receivable from these customers totaled $11.9 million at September 30, 2022 and $10.7 million at June 30,2022.

 

  

Three Months Ended

December 31,

  

Six Months Ended

December 31,

 
  

2017

  

2016

  

2017

  

2016

 
                 

Customer 1

 $19,134  $15,074  $32,292  $32,152 

Customer 2

  4,079  

 

(a)   7,239  

 

(a) 
  $23,213  $15,074  $39,531  $32,152 
12

(a)   Sales were less than 10% of the respective period’s total revenues.


10

We buy certain products, including beta-alanine, from a limited number of raw material suppliers.suppliers who meet our quality standards. The loss of any of these suppliers could have a material adverse impact on our net sales and net income. Raw material purchases from any one supplier representing 10% or more of the respective period’speriod’s total raw material purchases were as follows (in(dollars in thousands):

  

Three Months Ended

September 30,

 
  

2022

  

2021

 
         

Supplier 1

 $2,832  $3,368 

Supplier 2

 

(a)

   2,060 
  $2,832   5,428 

(a)

Sales were less than 10% of the respective period’s total raw material purchases.

  

  

Three Months Ended

December 31,

  

Six Months Ended

December 31,

 
  

2017

  

2016

  

2017

  

2016

 
                 

Supplier 1

 

$

(a)  

 

(a)  $2,992  

 

(a) 

Supplier 2

  1,684  

 

(a)   2,911  

 

(a) 

Supplier 3

  1,718  

 

(a)  

 

(a)  

 

(a) 
  $3,402     $5,903    

(a) Purchases were less than 10% of the respective period’s total raw material purchases.

G.H. Segment Information

 

Our business consists of two segments for financial reporting purposes,purposes. The two segments are identified as (i) private labelprivate-label contract manufacturing, which primarily relates to the provision of private labelprivate-label contract manufacturing services to companies that market and distribute nutritional supplements and other health care products;products, and (ii) patent and trademark licensing, which primarily includes direct raw material sales and royalty income from our license and supply agreements associated with the sale and use of beta-alanine under our CarnoSyn® and SR CarnoSyn® trade names.

 

We evaluate performance of these segments based on a number of factors. The primary performance measures for each segment are net sales and income or loss from operations before the allocation of certain corporate allocations.level expenses. Operating income or loss for each segment does not include corporate general and administrative expenses, interest expense and other miscellaneous income and expense items. Corporate general and administrative expenses, which are not allocated to any segment, include, but are not limited to:to human resources, corporate legal, finance, information technology, and other corporate level related expenses.expenses, which are not allocated to any segment. Transfers of raw materials between segments are recorded at cost. The accounting policies of our segments are the same as those described in the summary of significant accounting policies in Note A above and in the consolidated financial statements included in our 20172022 Annual Report.

 

Our operating results by business segment were as follows (in thousands):

 

  

Three Months Ended

December 31,

  

Six Months Ended

December 31,

 
  

2017

  

2016

  

2017

  

2016

 

Net Sales

                

Private label contract manufacturing

 $29,355  $23,864  $51,577  $51,243 

Patent and trademark licensing

  3,980   6,695   9,832   13,383 

Total Net Sales

 $33,335  $30,559  $61,409  $64,626 

  

Three Months Ended

December 31,

  

Six Months Ended

December 31,

 
  

2017

  

2016

  

2017

  

2016

 

Income from Operations

                

Private label contract manufacturing

 $3,385  $2,148  $5,641  $5,462 

Patent and trademark licensing

  504   2,340   1,692   4,240 

Income from operations of reportable segments

  3,889   4,488   7,333   9,702 

Corporate expenses not allocated to segments

  (1,608

)

  (1,375

)

  (3,169

)

  (3,053

)

Total Income from Operations

 $2,281  $3,113  $4,164  $6,649 
  

Three Months Ended

September 30,

 
  

2022

  

2021

 

Net Sales

        

Private-label contract manufacturing

 $41,776  $33,594 

Patent and trademark licensing

  1,351   4,746 

Total Net Sales

 $43,127  $38,340 

 

 

 

Total Assets

 

December 31,

2017

  

June 30,

2017

 

Private label contract manufacturing

 $72,115  $60,489 

Patent and Trademark Licensing

  12,472   12,122 

Total

 $84,587  $72,611 
  

Three Months Ended

September 30,

 
  

2022

  

2021

 

Income from Operations

        

Private-label contract manufacturing

 $3,244  $3,700 

Patent and trademark licensing

  347   2,636 

Income from operations of reportable segments

  3,591   6,366 

Corporate expenses not allocated to segments

  (2,049

)

  (2,108

)

Total Income from Operations

 $1,542  $4,228 

  

September 30,

2022

  

June 30,

2022

 

Total Assets

        

Private-label contract manufacturing

 $120,263  $115,649 

Patent and trademark licensing

  29,305   30,354 
  $149,568  $146,003 

 

11
13

Our private labelprivate-label contract manufacturing products are sold both in the U.S. and in markets outside the U.S.U.S., including Europe, Canada, Australia, and Asia, as well as Canada,New Zealand, Mexico and South Africa.Asia. Our primary marketmarkets outside the U.S. is Europe.are Europe and Asia. Our patent and trademark licensing activities are primarily based in the U.S.

 

Net sales by geographic region, based on the customerscustomers’ location, were as follows (in thousands):

 

  

Three Months Ended

December 31,

  

Six Months Ended

December 31,

 
  

2017

  

2016

  

2017

  

2016

 
                 

United States

 $16,426  $13,654  $31,620  $28,879 

Markets outside of the United States

  16,909   16,905   29,789   35,747 

Total

 $33,335  $30,559  $61,409  $64,626 

  

Three Months Ended

September 30,

 
  

2022

  

2021

 

United States

 $29,832  $23,495 

Markets outside of the United States

  13,295   14,845 

Total

 $43,127  $38,340 

 

Products manufactured by NAIEour Swiss subsidiary ("NAIE") accounted for 81%77% of net sales in markets outside the U.S. for the three months ended December 31, 2017, and 79% for the six months ended December 31, 2017.September 30, 2022. Products manufactured by NAIEour Swiss subsidiary ("NAIE") accounted for 60%80% of net sales in markets outside the U.S. for the three months ended December 31, 2016,September 30, 2021. and 53% for the six months ended December 31, 2016. No products manufactured by NAIE were sold in the U.S. markets during the three month or six month periods ended December 31, 2017September 30, 2022 and 2016.2021.

 

Assets and capitalLong-lived assets by geographic region, based on the location of the company or subsidiary at which they were located or made, were as follows (in thousands):

  

September 30, 2022

  

June 30, 2022

 

United States

 $50,732  $43,769 

Europe

  21,788   22,505 

Total Long-Lived Assets

 $72,520  $66,274 

Total assets by geographic region, based on the location of the company or subsidiary at which they were located or made, were as follows (in thousands):

  

September 30, 2022

  

June 30, 2022

 

United States

 $93,248  $83,443 

Europe

  56,320   62,560 

Total Assets

 $149,568  $146,003 

Capital expenditures by geographic region, based on the location of the company or subsidiary at which they were located or made, were as follows (in thousands):

  

Three Months Ended

September 30,

 
  

2022

  

2021

 

United States

 $7,720  $18,201 

Europe

  47   143 

Total Capital Expenditures

 $7,767  $18,344 

  

  

Long-Lived Assets

  

Total Assets

  

Capital Expenditures

 
                  

Six Months Ended

 
  

December 31,

2017

  

June 30,

2017

  

December 31,

2017

  

June 30,

2017

  

December 31,

2017

  

December 31,

2016

 

United States

 $10,461  $10,753  $53,353  $47,777  $426  $1,812 

Europe

  8,272   7,383   31,234   24,834   1,669   1,550 
  $18,733  $18,136  $84,587  $72,611  $2,095  $3,362 

H.I. Income Taxes

The Tax Cuts and Jobs Act (the “Act”) was enacted on December 22, 2017. Among other things, the Act reduces the U.S. federal corporate tax rate to 21% and requires companies to pay a one-time deemed repatriation transition tax on earnings of U.S.-owned foreign subsidiaries that were previously tax deferred. At December 31, 2017, we had not completed our accounting for the tax effects of the Act; however, in certain cases, as described below and in accordance with SAB118, we made a reasonable estimate of the effects on our existing deferred tax balances and the one-time transition tax. In other cases, we were not able to make a reasonable estimate and continue to account for those items based on our existing accounting under ASC 740, Income Taxes. For the items for which we did determine a reasonable estimate, we recognized a provisional amount as a discrete component of our provision for income taxes. The impact of the Tax Legislation may differ from these estimates, possibly materially, during the one-year measurement period ending December 22, 2018 due to, among other things, further refinement of our calculations, changes in interpretations and assumptions we made, guidance that may be issued and actions we may take as a result of the Act.

 

To determine our quarterly provision for income taxes, we use an estimated annual effective tax rate, thatwhich is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions to which we are subject. Certain significant or unusual items are separately recognized as discrete items in the quarter in which they occur and can be a source of variability in the effective tax rate from quarter to quarter. We recognize interest and penalties related to uncertain tax positions, if any, as an income tax expense.

 

TheOur effective tax rate for the three months ended December 31, 2017September 30, 2022 was 153.1% and the effective tax rate for the six months ended December 31, 2017 was 97.31%20.1%. In comparison, the Our effective tax rate for the three months ended December 31, 2016September 30, 2021 was 29.6 % and the effective tax rate for the six months ended December 31, 2016 was 30.1%22.5%. The Our effective tax rates for the three and six months ended December 31, 2017 differ from the estimatedfiscal 2023 and fiscal 2022 U.S. federal statutory rate of 28.06%21% primarily due to the impact of the Act's required one-time transition tax and the reevaluation of our deferred taxes, offset by the favorable impact of foreign earnings taxed at less than the U.S. statutory rate. As a fiscal taxpayer, our U.S. federal statutory rate for the year ending June 30, 2018 is estimated to be 28.06% and is a blended rate of the historic 35% statutory rate and the newly enacted 21% rate. We expect our U.S. federal statutory rate to be 21% for fiscal years beginning after June 30, 2018.

12

As part of the Act, we are required to recognize aone-time deemed repatriation transition tax based on our total post-1986 earnings and profits (E&P) from our Swiss subsidiary NAIE. This accumulated E&P amount has historically been considered permanently reinvested thereby allowing us to defer recognizing any U.S.state income tax on the amount. As a result of the Act we recorded a provisional amount for our one-time transition tax liability resulting in an increase in income tax expense during the three and six months ended December 31, 2017 of $1,815,966, which was treated as a discrete expense. In accordance with the provisions of the Act, we will elect to pay this tax over an eight-year period. Further, the transition tax is based in part on the amount of those earnings held in cash and other specified assets. This amount may change when we finalize the calculation at the conclusion of fiscal 2018. As of December 31, 2017, we no longer consider undistributed foreign earnings from NAIE as indefinitely reinvested. As a result, we have recorded $775,000 in estimated foreign withholding taxes on the amounts deemed repatriated under the Act, which was also treated as a discrete expense during the period.

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates for each of the jurisdictions in which we operate, and the tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. As of December 31, 2017, we remeasured certain deferred tax assets and liabilities based on the tax rates expected to apply in the future. For deferred tax asset and liability balances we expect to reverse during fiscal 2018 we used the blended U.S. statutory rate of 28.06% and for amounts expected to reverse in future periods we used the newly enacted 21% tax rate. However, we are still analyzing certain aspects of the Act and refining our calculations accordingly. This analysis and refinement could potentially affect the measurement of these balances or give rise to new deferred tax amounts. The provisional amount we recorded from our remeasurement of our deferred tax balance was $664,000 and was treated as a discrete expense for the three and six months ended December 31, 2017.taxes.

 

We record valuation allowances to reduce our deferred tax assets to an amount that we believe is more likely than not to be realized. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will ultimately be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. During the three and sixmonths ended December 31, 2017,September 30, 2022, there was no change to our valuation allowance.allowance for our deferred tax assets.

14

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates for each of the jurisdictions in which we operate. Deferred tax assets and liabilities are expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled using the tax rates then in effect. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date for such new rates.

 

We are subject to taxation in the U.S., Switzerland and various U.S. state jurisdictions. Our U.S. tax returns for the fiscal years ended June 30,2014 and forward are subject to examination by U.S. tax authorities and for fiscal yearsyear ended June 30, 20072015 and forward are subject to examination by the U.S. tax authorities. Our state tax returns for the fiscal years ended June 30, 2018 and forward are subject to examination by the state tax authorities. Our Swiss tax filingsreturns for the fiscal year ended June 30, 2021 30,2015and forward are subject to examination by the Swiss tax authorities.

 

It is our policy to establish reserves based on management’smanagement’s assessment of exposure for certain positions taken in previously filed tax returns that may become payable upon auditexamination by tax authorities. Our tax reserves are analyzed quarterly, and adjustments are made as events occur that we believe warrant adjustments to thethose reserves. There were no adjustments to these reserves in the three and six monthsmonth period ended December 31, 2017.September 30, 2022.

 

On September 26, 2022, NAIE declared and paid a dividend to NAI in the amount of $7.4 million. As part of the Tax Cuts and Jobs Act of 2017 (the Tax Act), we were required to recognize a one-time deemed repatriation transition tax during the fiscal year ended June 30, 2018 based on our total post-1986 earnings and profits (E&P) from NAIE. NAI paid the required 5% withholding tax to the Swiss tax authorities, which expense was already accrued as part of the Tax Act. U.S. taxes were recognized and paid as part of the Tax Act. We do not expect any additional US or Swiss tax liability as a result of this dividend.

 

I.J. Treasury Stock

 

On June2,2011,We purchase shares under a stock repurchase plan (“Repurchase Plan”) authorized by the Board of Directors authorized the repurchase of up to $2.0 million of our common stock. On February 6, 2015, the Board of Directors authorized a $1.0 million increase to our stock repurchase plan bringing theDirectors. The total authorized repurchase amount to $3.0 million. On May 11, 2015, the Board of Directors authorized a $2.0 million increase to our stock repurchase plan bringing the total authorized repurchase amount to $5.0 million. On March 28, 2017, the Board of Directors authorized a $2.0 million increase to our stock repurchase plan bringing the total authorized repurchase amount to $7.0is $18.0 million. Under the repurchase plan,Repurchase Plan, we may, from time to time, purchase shares of our common stock, depending upon market conditions. When we do so we may purchase the sharesconditions, in open market or privately negotiated transactions.

 

During thethree and six months ended December 31, 2017 and December 31, 2016, we did not repurchase any shares under this repurchase plan.

During Stock repurchases for the three months ended December 31, 2017,September 30, 2022 we acquired 7,264 shares in connection with restricted stock shares that vested during that year at a weighted average cost of $10.80 per share and a total cost of $78,000. During the six months ended December 31, 2017, we acquired 7,998 shares in connection with restricted stock shares that vested during that period at a weighted average cost of $10.79 per share and a total cost of $86,000. Duringwere as follows:

  

Shares

  

Average Cost

  

Total Cost (in

thousands)

 

Shares purchased under Repurchase Plan

  46,795  $10.62  $497 

Shares acquired in connection with stock option exercises

         

Shares acquired from employees for restricted stock vesting

         

Total

  46,795     $497 

Stock repurchases for the three months ended December 31, 2016,September 30, 2021 wewere as follows:

  

Shares

  

Average Cost

  

Total Cost (in

thousands)

 

Shares purchased under Repurchase Plan

    $  $ 

Shares acquired in connection with stock option exercises

         

Shares acquired from employees for restricted stock vesting

  692   14.20   10 

Total

  692      $10 

Stock repurchase costs include commissions and fees.

Shares acquired367 shares from employees in connection withfor restricted stock shares that vested during the period at a weighted average cost of $12.30 per sharevesting and a total cost of $5,000. During the six months ended December 31, 2016, we acquired 6,404 shares from employees in connection with restricted stock shares that vested during the period at a weighted average cost of $13.09 per share and a total cost of $84,000.

13

These sharesoptions exercises were returned to NAIus by the related employees and in return NAIwe paid each employee’s required tax withholding required as a result ofresulting from the vesting of the restricted shares. The valuation of the shares acquired and thereby the number of shares returned to NAIus was calculated based on the closing share price on the date the restricted shares vested.

  

 

J.K. Derivatives and Hedging

 

We are exposed to gains and losses resulting from fluctuations in foreign currency exchange rates relating to forecasted product sales denominated in foreign currencies and to other transactions of NAIE, our foreign subsidiary denominated in foreign currencies.subsidiary. As part of our overall strategy to manage the level of exposure to the risk of fluctuations in foreign currency exchange rates, we sometimesmay use foreign exchange contracts in the form of forward contracts. To the extent we enter into such contracts, there can be no guarantee any such contracts will be effective hedges against our foreign currency exchange risk.

 

15

As of December 31,September 30, 2022, 2017,we had forward contracts designated as cash flow hedges primarily to protect against the foreign exchange risks inherent in our forecasted sales of products at prices denominated in currencies other than the U.S. Dollar. These contracts are expected to be settled through August 2019.September 2023. For derivative instruments that are designated and qualify as cash flow hedges, we record the effective portion of the gain or loss on the derivative in accumulated other comprehensive income (loss)(“OCI”) as a separate component of stockholders’ equity and subsequently reclassify these amounts into earnings in the period during which the hedged transaction is recognized in earnings.

 

For foreign currency contracts designated as cash flow hedges, hedge effectiveness is measured using the spot rate. Changes in the spot-forward differential are excluded from the test of hedge effectiveness and are recorded currently in earnings as interest expense or income.revenue. We measure effectiveness by comparing the cumulative change in the hedge contract with the cumulative change in the hedged item. No hedging relationships were terminated as a result of ineffective hedging for the three months ended September 30, 2022 and September 30, 2021.

We monitor the probability of forecasted transactions as part of the hedge effectiveness testing on a quarterly basis. During the three months ended September 30, 2022 and September 30, 2021, we did not have any losses or gains related to the ineffective portion of our hedging instruments during the three and six months ended December 31, 2017. During the three and six months ended December 31, 2016, we recorded a $92,000 gain related to the ineffective portion of our hedging instruments to other income. None of our foreign currency forward contracts were terminated as a result of ineffective hedging or forecasted transactions no longer probable of occurring for foreign currency forward contracts. We monitor the probability of forecasted transactions as part of our hedge effectiveness testing on a quarterly basis.instruments.

 

As of December 31,September 30, 2022, 2017,the notional amounts of our foreign exchange contracts designated as cash flow hedges were approximately $52.6$33.3 million (EUR 45.329.1 million). As of December 31, 2017,September 30, 2022, a net lossgain of approximately $2.7$2.9 million, offset by $0.7 million of deferred taxes, related to derivative instruments designated as cash flow hedges was recorded in OCI. It is expected that $2.0 millionthe entire amount will be reclassified into earnings in the next 12 months along with the earnings effects of the related forecasted transactions.

 

As ofFor foreign currency contracts December 31, 2017not, designated as cash flow hedges, changes in the fair value of our cash flow hedges was a liability of $2.7 million, of which $2.1 million was classified as a current liability, and $609,000 was classifiedthe hedge are recorded directly to foreign exchange gain or loss in other noncurrent liabilitiesincome in our Consolidated Balance Sheets.an effort to offset the change in valuation of the underlying hedged item. During the three months ended December 31, 2017,September 30, 2022 we recognized $731,000 of net lossesentered into forward contracts in OCI and reclassified $428,000 of losses from OCIorder to revenue. During the six months ended December 31, 2017, we recognized $2.9 million of net losseshedge foreign exchange risk associated with our lease liability at NAIE, which is denominated in OCI and reclassified $850,000 of losses from OCI to revenue.Swiss Francs (CHF). As of JuneSeptember 30, 2022, 30,2017,$422,000 of the fair valuenotional amounts of our foreign exchange contracts not designated as cash flow hedges was classified in accrued liabilities, andwere approximately $12.3 million (CHF 12.0 million).

We are exposed to interest rate fluctuations related to our $10 million Term Note with Wells Fargo, which carries a variable interest rate of 1.80% above the SOFR rolling $99,00030 was classified other noncurrent liabilities in-day average. To manage our Consolidated Balance Sheets. Duringexposure to this variable rate, on August 23, 2021, we entered into a floored interest rate swap that fixes our all-in rate on this loan to 2.4% for thefirst three months endedyears of the term loan. Fluctuations in the relation of our contractual swap rate to current market rates are recorded as an asset or liability with an offset to OCI at the end of each reporting period. Interest expense is adjusted for the difference between the actual SOFR spread and the swap contractual rate such that our effective interest expense for each period is equal to our hedged rate of December 31, 2016, 2.4%.we recognized $2.3 million of net gains in OCI and reclassified $213,000 of gains from OCI to revenue. During the six months ended December 31, 2016, we recognized $1.8 million of net gains in OCI and reclassified $271,000 of gains from OCI to revenue. 

  

 

K.L. Contingencies

 

From time to time, we become involved in various investigations, claims and legal proceedings that arise in the ordinary course of our business. These matters may relate to product liability, employment, intellectual property, tax, regulation,regulatory, contract or other matters. The resolution of these matters as they arise will may be subject to various uncertainties and, even if such claims are without merit, could result in the expenditure of significant financial and managerial resources. While unfavorable outcomes are possible, based on available information, we generallycurrently do not believe the resolution of these matters will result in a material adverse effect on our business, consolidated financial condition, or results of operations. However, a settlement payment or unfavorable outcome could be greater than we currently anticipate and if so, could adversely impact our results of operations. Our evaluation of the likely impact of these actions could change in the future and we could have unfavorable outcomes we do not expect.

 

COVID-19 Pandemic

We continue to monitor and evaluate the risks to public health and the impact on overall global business activity related to the COVID-19 pandemic, including its potential impacts on our employees, customers, suppliers and financial results. As the situation remains fluid, it is difficult to predict the duration and scope of the pandemic and its impact on our business. However, it may result in a material adverse impact to our financial position, operations and cash flows if conditions persist or worsen.

16

14

 

ITEM 2.MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis is intended to help you understand our financial condition and results of operations for the three and six months ended December 31, 2017.September 30, 2022. You should read the following discussion and analysis together with our unaudited condensed consolidated financial statements and the notes to the condensed consolidated financial statements included under Item 1 in this Quarterly Report, as well as the risk factors and other information included in our 20172022 Annual Report and other reports and documents we file with the SEC. Our future financial condition and results of operations will vary from our historical financial condition and results of operations described below based on a variety of factors.

 

Executive Overview

 

The following overview does not address all of the matters covered in the other sections of this Item 2 or other items in this Quarterly Report ornor does it contain all of the information that may be important to our stockholders or the investing public. You should read this overview in conjunction with the other sections of this Item 2 and this Quarterly Report.

 

Our primary business activity is providing private labelprivate-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbsherbal and other nutritional supplements, as well as other health care products, to consumers both within and outside the U.S. Historically, our revenue has been largely dependent on sales to two or three private labelprivate-label contract manufacturing customers and thus sensitivesubject to variations in the timing of such customerscustomers’ orders, which variations in turn have beenis impacted by such customers’ internal marketing programs, supply chain management, entry into new markets, new product introductions, the demand for such customers’ products, and general industry and economic conditions. Our revenue also includes raw material sales and royalty and licensing revenue generated from our patent estate pursuant to license and supply agreements with third parties, forgranting them the right to use our patents, trademarks and other intellectual property in connection with the distribution and use of the ingredient known as beta-alanine sold under our CarnoSyn® and SR CarnoSyn® trademarks.

 

A cornerstone of our business strategy is to achieve long-term growth and profitability and to diversify our sales base. We have sought and expect to continue to seek to diversify our sales by developing relationships with additional, quality-oriented, private labelprivate-label contract manufacturing customers, and commercializing our patent estate through sales of beta-alanine under our CarnoSyn® and SR CarnoSyn® trade names, royalties from license agreements, and potentially additional contract manufacturing opportunities with these licensees.

 

During the first sixthree months of fiscal 2018,2023, our net sales were 5% lower12% higher than in the first sixthree months of fiscal 2017.  Private label2022. Private-label contract manufacturing sales increased 1%24% primarily due primarily to the sale of new productshigher sales to existing customers and higher volumes of current products to existingour two largest customers, partially offset by the timing and shipment of orders of current productsdecreased sales to existingother smaller customers and discontinued customer relationships. Our first quarter fiscal 2018 contract manufacturinglower average exchange rates applied to sales declined 19%denominated in Euro as compared to the same periodprior year period. Our foreign exchange rates as applied to sales denominated in Euro decreased to a weighted average of 1.12 EUR/USD in the prior year primarily from reduced orders from our largest customer for specific products associated with an inventory reduction program. During our second quarterfirst three months of fiscal 2018, our contract manufacturing sales increased 23% as2023 compared to a weighted average of 1.18 EUR/USD during the comparable prior year period primarily due to an increase in sales to our largest customer to historical levels and shipmentfirst three months of new products under our previously announced expanded relationship. fiscal 2022. Revenue concentration risk for our largest private labelprivate-label contract manufacturing customer as a percentage of our total net sales increased to 53%remained consistent at 35% for the sixthree months ended December 31, 2017September 30, 2022 as compared to 50% in the first sixthree months of fiscal 2017.ended September 30, 2021. We expect our annualized fiscal 2018year 2023 revenue concentration for thisour largest customer to be higher thancomparable to fiscal 2017.2022 revenue.

 

During the first sixthree months of fiscal 2018, CarnoSyn® beta-alanine2023, patent and trademark licensing revenue decreased 27%72% to $9.8$1.4 million, as compared to $13.4revenue of $4.8 million for the first sixthree months of fiscal 2017.2022. The decrease in beta-alaninepatent and trademark licensing revenue during the first three months of fiscal 2023 was primarily due to decreased material shipmentsa decrease in orders from existing customers as a result of market and seasonalinflationary factors and lower average material sales prices. During the quarter ended December 31, 2017, the sports nutrition retail market conditions declined most notablyalong with a general slowdown in the standard “brickSports Nutrition sales channel. Included in the market factors is the fact that the first three months of fiscal 2022 benefited from a ramp up of Sports Nutrition sales activity due to easing COVID restrictions on athletic activities with no corresponding activity in the first three months of fiscal 2023.

We continue to invest in research and mortar” sales channels as products transitioned to higher levels of internet based sales. This transition resulted in excess inventory in certain channels and delayed the re-order ratesdevelopment for many of our customer brands. Additionally, while we still have active patents covering instant release CarnoSyn® beta-alanine, we experienced increased competition from companies selling generic beta-alanine during the current quarter resulting in certain customers discontinuing the use of our CarnoSyn® beta-alanine. In  addition to legal actions we have prosecuted and others we may institute, to offset this decline, we have increased our sales and marketing activities to consumers, customers, potential customers, and brand owners on multiple platforms to promote and reinforce the features and benefits of utilizing CarnoSyn® beta-alanine. As we enter our third quarter ending March 31, 2018, our re-order rates have improved for many of our customer brands suggesting improved sports nutrition retail market conditions. Additionally, our SR CarnoSyn® raw material sales continued to rise during the current quarter as more brands adopted product offerings of this effectivesustained release delivery system. There canWe believe SR CarnoSyn® may provide a unique opportunity within the growing Wellness and Healthy Aging markets. We believe our recent efforts to refine our formulations and product offerings will be no assurance that our salespositively received and marketing efforts or the recent apparent improvementresult in retail market conditions will reverse or decelerate potential future declinessignificant opportunity for increased SR CarnoSyn® sales.

17

 

To protect our CarnoSyn® business and its underlying patent estate,our patents, trademarks and other intellectual property, we incurred litigation and patent compliancecompliance expenses of approximately $1.7 million$30,000 during the first sixthree months of fiscal 2018 and $2.02023 as compared to $0.1 million during the comparable period in fiscal 2017.   We describe2022. Our legal expense associated with our effortsCarnoSyn® business has remained low as we have no active litigation and the current run-rate of expenses is only related to protect ourmaintenance of the patent estate in more detail under Item 1 of Part II of our 2017 Annual Report.estate. Our ability to maintain or further increase our beta-alanine royalty and licensing revenue will depend in large part on our ability to develop a market for our sustained release form of beta-alanine marketed under our SR Carnosyn® tradename, maintenance ofCarnoSyn® trademark, maintain our patent rights, the availability ofobtain the raw material beta-alanine when and in the amounts needed, the ability to expand distribution of beta-alanine to new and existing customers, the ability to further commercialize our existing patents, and the continued compliance by third parties with our license agreements and our patent, trademark and trademarkother intellectual property rights. During the remainder of fiscal 2023, we will continue our sales and marketing activities to consumers, customers, potential customers, and brand owners on multiple platforms to promote and reinforce the features and benefits of utilizing CarnoSyn® and SR CarnoSyn® beta-alanine.

 

15

Table

Based on our current sales order volumes and forecasts we have received from our customers, we now anticipate our fiscal 2023 consolidated net sales will be slightly up as compared to fiscal 2022. While sales are expected to increase during fiscal 2023 when compared to fiscal 2022, we anticipate operating income will be negatively impacted by changes in sales mix, unfavorable foreign exchange rates, and inflationary factors including increased operational costs impacted by increased labor, raw material, freight and supply chain costs.  We are working with both suppliers and customers to attempt to mitigate the expected negative impact on our fiscal 2023 financial results.  There can be no assurances our expectations will result in the currently anticipated increase in net sales and expected operating income levels.

Impact of Contents

COVID-19 on Our Business

The COVID-19 pandemic has resulted, and is likely to continue to result, in significant economic disruption and has and will likely continue to affect our business. Significant uncertainty exists concerning the magnitude of the impact and duration of the COVID-19 pandemic. Our facilities, located both in the United States and Europe, have maintained operations throughout the duration of the COVID-19 pandemic, however, there can be no assurance our facilities will continue to operate without interruption. Factors that derive from COVID-19 and the accompanying response, and that have or may negatively impact sales and gross margin in the future include, but are not limited to the following:

Limitations on the ability of our suppliers to manufacture, or procure from manufacturers, the materials included in the products we sell, or to meet delivery requirements and commitments;

Limitations on the ability of our employees to perform their work due to illness caused by the pandemic or due to other restrictions on our employees to keep them safe and the increased cost of measures taken to ensure employee health and safety;

Limitation on the availability of qualified individuals to adequately staff our manufacturing facilities;

Limitations on the ability of our suppliers to manufacture and meet timelines associated with capital improvement projects;

Limitations on the ability of our customers to conduct their business and purchase our products and services; and

Limitations on the ability of our customers to pay us on a timely basis.

We will continue to actively monitor the situation and may take further actions to alter our business operations as may be required by federal, state or local authorities or that we determine are in the best interests of our employees, customers, suppliers and shareholders. While we are unable to determine or predict the nature, duration, or scope of the overall impact the COVID-19 pandemic will have on our business, results of operations, liquidity or capital resources, we believe we will be able to remain operational and our working capital will be sufficient for us to remain operational even as the longer-term consequences of this pandemic become known.

 

During the remainder of fiscal 2018, year 2023, we also plan to continue our focus on:

 

Leveraging our state-of-the-art, certified facilities to increase the value of the goods and services we provide to our highly valued private-label contract manufacturing customers, and develop relationships with additional quality oriented customers;

Expanding the commercialization of our beta-alanine patent estate through raw material sales, developing a market for our sustained release form of beta-alanine marketed under our SR Carnosyn® tradename, new contract manufacturing opportunities, license agreements and protecting our proprietary rights;

Leveraging our state-of-the-art, certified facilities to increase the value of the goods and services we provide to our highly valued private-label contract manufacturing customers, and to assist us in developing relationships with additional quality oriented customers;

Completing construction on our new high-volume powder blending and packaging facility, which we expect to be operational by mid-to-late fiscal year 2023;

Expanding the commercialization of our beta-alanine patent estate through raw material sales, developing a new sales distribution channel under the Wellness and Healthy Aging category for our sustained release form of beta-alanine marketed under our SR CarnoSyn® trademark, exploiting new contract manufacturing opportunities license and royalty agreements, and protecting our proprietary rights; and

Improving operational efficiencies and managing costs and business risks to improve profitability.

18

 

Discussion of Critical Accounting Policies and Estimates

 

The preparation of our financial statements requires that we make estimates and assumptions that affect the amounts reported in our financial statements and their accompanying notes. We have identified certain policies we believethe following as our most critical accounting estimates, which are those that are most important to the portrayal of ourthe Company’s financial condition and results, and that require management’s most subjective and complex judgments. Information regarding our other significant accounting estimates and policies are disclosed in Note 1 of operations. These policies requireItem 1 of this report and are disclosed in the application2022 Annual Report.

Revenue Recognition — Revenue is measured as the net amount of significant judgment by our management. We baseconsideration expected to be received in exchange for fulfilling one or more performance obligations. For certain contracts with volume rebates and discounts, our estimates on our historical experience, industry standards,of future sales used to assess the volume rebate and various other assumptions we believediscount estimates are reasonable under the circumstances. Actual results couldsubject to a high degree of judgement and may differ from these estimates under different assumptions or conditions. An adverse effect on our financial condition,actual sales due to, among other things, changes in financial condition,customer orders and results of operations could occur if circumstances change that alter the various assumptions or conditions used in such estimates and assumptions.

Our critical accounting policies are discussed under Item 7 of our 2017 Annual Report and recent accounting pronouncements are discussed under Item A to our Notes to Condensed Consolidated Financial Statements contained in this Quarterly Report. There have been no significant changes to these policies or pronouncements during the six months ended December 31, 2017.raw material availability. 

 

Results of Operations

 

The results of our operations for the three and six months ended December 31September 30 were as follows (in(dollars in thousands):

 

 

Three Months Ended

  

Six Months Ended

  

Three Months Ended

 
 

December 31,

  

December 31,

  

September 30,

 
 

2017

  

2016

  

% Change

  

2017

  

2016

  

% Change

  

2022

 

2021

 

% Change

 

Private label contract manufacturing

 $29,355  $23,864   23% $51,577  $51,243   1%

Private-label contract manufacturing

 $41,776  $33,594  24

%

Patent and trademark licensing

  3,980   6,695   (41)%  9,832   13,383   (27)%  1,351   4,746  (72

)%

Total net sales

  33,335   30,559   9%  61,409   64,626   (5)% 43,127  38,340  12

%

Cost of goods sold

  26,713   24,064   11%  48,417   50,462   (4)%  37,756   30,059  26

%

Gross profit

  6,622   6,495   (2)%  12,992   14,164   (8)% 5,371  8,281  (35

)%

Gross profit %

  19.9%  21.3%      21.2%  21.9%     12.5

%

 21.6

%

   
                         

Selling, general and administrative expenses

  4,341   3,382   28%  8,828   7,515   17% 3,829  4,053  (6

)%

% of net sales

  13.0%  11.1%      14.4%  11.6%     8.9

%

 10.6

%

   
                             

Income from operations

  2,281   3,113   (27)%  4,164   6,649   (37) 1,542  4,228  (64

)%

% of net sales

  6.8%  10.2%      6.8%  10.3%     3.6

%

 11.0

%

   
                         

Total other income

  202   387   (48)%  310   437   (29)%

Total other expense

  (224

)

  (26

)

 762

%

Income before income taxes

  2,483   3,500   (29)%  4,474   7,086   (37)% 1,318  4,202  (69

)%

% of net sales

  7.4%  11.5%      7.3%  11.0%     3.1

%

 11.0

%

   
                         

Provision for income taxes

  3,801   1,034   268%  4,358   2,130   105%  265   946  (72

)%

Net (loss) income

 $(1,318) $2,466   (153)% $116  $4,956   (98)%

Net income

 $1,053  $3,256  (68

)%

% of net sales

  (4.0)%  8.1%      0.2%  7.7%     2.4

%

 8.5

%

   

 

Private-label contract manufacturing net sales increased 23%24% during the three months ended December 31, 2017 and 1% during the six months ended December 31, 2017,September 30, 2022, when compared to the same periodsperiod in the prior year. These increases were due primarily to the sale of new products to existing customers and higher volumes of current products to existing customers partially offset by the timing and shipment of orders of current products to existing customers and discontinued customer relationships. Net sales to our largest customer represented a majority of theThe increase in our private label contract manufacturing sales during the three months ended December 31, 2017September 30, 2022 was primarily due to increased sales to our two largest customers, partially offset by decreased sales to other smaller customers and were primarilylower average exchange rates applied to sales denominated in Euro as compared to the resultprior year period. Our foreign exchange rates as applied to sales denominated in Euro decreased to a weighted average of increased orders1.12 EUR/USD in the first three months of current products and ordersfiscal 2023 compared to a weighted average of new products.

16

fiscal 2022.

 

Net sales from our patent and trademark licensing segment decreased 41%72% during the three months ended December 31, 2017 and decreased 27% during the six months ended December 31, 2017,September 30, 2022, when compared to the same periodsperiod in the prior year. The decrease in beta-alanine raw material salespatent and trademark licensing revenue during the three months ended September 30, 2022 was primarily due to decreased shipments of beta alaninea decrease in orders from existing customers as a result of market and seasonalinflationary factors and lower averagealong with a general slowdown in the Sports Nutrition sales prices forchannel. Included in the material.market factors is the fact that the first three months of fiscal 2022 benefited from a ramp up of Sports Nutrition sales activity due to easing COVID restrictions on athletic activities with no corresponding activity in the first three months of fiscal 2023.

19

 

The change in gross profit margin betweenfor the three and six month periodsmonths ended December 31, 2017September 30, 2022, was as follows:

 

  

Three Months

  

Six Months

 
  

Ended

  

Ended

 
         

Contract manufacturing(1)

  3.2

%

  0.8

%

Patent and trademark licensing(2)

  (4.6)  (1.6)

Total change in gross profit margin

  (1.4

%)

  (0.8%)

Three Months

Ended

Contract manufacturing(1)

(2.6

)%

Patent and trademark licensing(2)

(6.5

)

Total change in gross profit margin

(9.1

)%

 

1

1Private labelPrivate-label contract manufacturing gross profit margin as a percentage of consolidated net sales increased 3.2decreased 2.6 percentage points during the three months ended December 31, 2017 and increased 0.8 percentage points during the six months ended December 31, 2017September 30, 2022 when compared to the comparable prior year periods. These increases wereperiod. The decrease in gross profit as a percentage of sales for private-label contract manufacturing during the first quarter of fiscal 2023 is primarily due to an increase in per unit manufacturing costs, particularly related to increased labor and freight costs, and unfavorable foreign exchange rates applied to sales and favorable product sales mix.denominated in Euro.

 

2

Patent and trademark licensing gross profit margin as a percentagepercentage of consolidated net sales decreased 4.66.5 percentage points during the three months ended December 31, 2017 and decreased 1.6 percentage points during the six months ended December 31, 2017September 30, 2022 when compared to the comparable prior year periods. These decreases wereperiod. The decrease in margin contribution during the three month period ended September 30, 2022 was primarily due to decreased raw materialpatent and trademark licensing net sales and decreased royalty income as a percentage of total consolidated net sales, partially offset byas patent and trademark licensing historically provides higher profit margins than our private-label contract manufacturing business. The three months ended September 30, 2021 also included a favorable raw material costs.change in estimate regarding certain volume rebate programs that was not repeated during the three months ended September 30, 2022.

 

Selling, general and administrativeadministrative expenses increased $1.0decreased $0.2 million, or 28%6%, during the three months ended December 31, 2017 and increased $1.3 million, or 17%, during the six months ended December 31, 2017,September 30, 2022 as compared to the comparable prior year periods.  These increases were primarily due to increased marketing, advertising and research and development costs supporting our CarnoSyn® and SR CarnoSyn® brands and increased compensation costs partially offset by lower litigation costs.period.

 

Other income, net decreasedexpense increased $0.2 million during the three months ended December 31, 2017 and decreased $0.1 million during the six months ended December 31, 2017,September 30, 2022 when compared to the comparable period during the prior year periods.  These decreases wereyear. The increase was primarily due to unfavorable foreign exchange fluctuations.revaluation activity and fluctuations in unhedged foreign currency rates when compared to the same period in the prior fiscal year.

 

Our income tax expense increased $2.8decreased $0.7 million or 268%, during the three months ended December 31, 2017 and increased $2.2 million, or 105%, during the six months ended December 31, 2017, asSeptember 30, 2022 when compared to the comparable prior year periods.  The increases were primarily due to the discrete income tax expense amounts recorded as a result of the Tax Cuts and Jobs Act enacted on December 22, 2017. Among other things, the Act reduces the U.S. federal corporate tax rate to 21% and requires companies to pay a one-time deemed repatriation transition tax on earnings of U.S.-owned foreign subsidiaries that were previously tax deferred. At December 31, 2017, we have not completed our accounting for all of the tax effects of the Act; however, in certain cases, as described below and in accordance with SAB 118, we have made a reasonable estimate of the effects on our existing deferred tax balances and the one-time transition tax. In other cases, we have not been able to make a reasonable estimate and continue to account for those items based on our existing accounting under ASC 740, Income Taxes. For the items for which we were able to determine a reasonable estimate, we recognized a provisional amount as a discrete component of our provision for income taxes. The impact of the Act may differ from these estimates, possibly materially, during the one-year measurement period ending December 22, 2018 due to, among other things, further refinement of our calculations, changes in the interpretations and assumptions we made, guidance that may be issued and actions we may take as a result of the Act.

Included in our tax expense for the three and six months ended December 31, 2017 is $3.3 million of discrete tax items related to the Act. The discrete tax items include:

$1.8 million associated with a one-time transition tax that is calculated based on our total post-1986 earnings and profits (E&P) from our Swiss subsidiary NAIE. This accumulated E&P amount has historically been considered permanently reinvested thereby allowing us to defer recognizing any U.S. income taxes on the amount of such E&P.  However, under the Act we are required to pay this tax based on a deemed repatriation into the U.S. of such E&P. In accordance with the provisions of the Act, we will elect to pay this tax over an eight-year period.

17

As of December 31, 2017, we no longer consider undistributed foreign earnings from NAIE as indefinitely reinvested. As a result, we have recorded $775,000 in estimated foreign withholding taxes on the amounts deemed repatriated under the Act, which was also treated as a discrete expense during the period.

As of December 31, 2017, we remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. For balances we expect to reverse during fiscal 2018 we used the blended U.S. statutory rate of 28.06% and for amounts expected to reverse in future periods we used the newly enacted 21% tax rate. However, we are still analyzing certain aspects of the Act and refining our calculations, which could potentially affect the measurement of these balances or potentially give rise to new deferred tax amounts. The provisional amount recorded from the remeasurement of our deferred tax balance was $664,000.

Our effective tax rate, excluding the impact of the above noted discrete items, for the three months ended December 31, 2017 was 21.9% as compared to an effective tax rate of 29.6% for the three months ended December 31, 2016. As a fiscal taxpayer, our U.S. federal statutory rate for the year ended June 30, 2018 is estimated to be 28.06% and is a blended rate of the historic 35% statutory rate and the newly enacted 21% rate. The year over year improvement in our second fiscal quarter effective tax rate is primarily due to the reduction of the U.S. federal tax rate used in our estimated tax calculation, which reduced to a blended rate of 28.06% as compared to 34.0% used in the same period in the prior year. In addition, as this rate reduction was applied on a year to date basis the second quarter of 2018fiscal 2022. The decrease in income tax expense receivedwas primarily related to a benefit from the application of the lower rate to the first quarter of fiscal 2018decrease in pre-tax income thus further reducing the effective tax rate for the quarter. Our effective tax rate, for the six months ended December 31, 2017 excluding the impact of the above noted discrete items, was 24.6% as compared to an effective tax rate of 30.1% for the six months ended December 31, 2017. The improvement in our year to date fiscal 2018 effective tax rate as compared to the same period in the prior year is primarily due to the reduction of the U.S. federal tax rate used in our estimated tax calculation, which reduced to a blended rate of 28.06% as compared to 34.0% used in effective tax rate calculation the same period in the prior year.

 

We expect our U.S. federal statutory rate to be 21% for fiscal years beginning after June 30, 2018, which should further reduce our effective tax rate on an annualized basis.

20

 

Liquidity and Capital Resources

 

Our primary sources of liquidity and capital resources are cash flows provided by operating activities and the availability of borrowings under our credit facility. Net cash providedused by operating activities was $4.7$4.6 million duringfor the sixthree months ended December 31, 2017 asSeptember 30, 2022 compared to net cash provided by operating activities of $5.0$3.8 million duringin the comparable period in the prior fiscal year.

 

During the six months ended December 31, 2017,At September 30, 2022, changes in accounts receivable, used $4.5consisting of amounts due from our private-label contract manufacturing customers and our patent and trademark licensing activities, provided $2.6 million in cash compared to having provided $3.4using $2.4 million of cash during the comparable sixthree month period in the prior year. The decreaseincrease in cash provided by accounts receivable during the six month periodthree months ended December 31, 2017September 30, 2022 primarily resulted from the timing of sales and the related collections. Days sales outstanding was 3234 days during the sixthree months ended December 31, 2017 and 33September 30, 2022 as compared to 46 days duringfor the six months ended December 31, 2016.prior year period.

 

During the six months ended December 31, 2017, changesChanges in inventory used $4.2$7.5 million in cash during the three months ended September 30, 2022 compared to having provided $3.7using $4.7 million in the comparable prior year period. The increaseDuring the three months ended September 30, 2022, the change in cash provided byrelated to inventory during the period ended December 31, 2017 was primarily related to inventory purchased to support increased sales to our largest private label contract manufacturing customerthe difference in the amount and timing of orders and shipments.anticipated sales as compared to the same period in the prior year. Changes in accounts payable and accrued liabilities provided $6.9$1.0 million in cash during the sixthree months ended December 31, 2017September 30, 2022 compared to having used $6.7providing $0.3 million during the sixthree months ended December 31, 2016.September 30, 2021. The change in cash flow activity related to accounts payable and accrued liabilities is primarily due to inventory associated with increased sales associated with our largest customer and timing of inventory receipts and payments.

During the six months ended December 31, 2017, NAIE’s operations provided $2.1 million of our operating cash flowwas primarily due to the timing of inventory receipts payments and sales.payments.

 

Cash used in investing activities duringin the sixthree months ended December 31, 2017September 30, 2022 was $3.6$7.8 million compared to $3.3$18.3 million duringin the comparable six month period last year.prior year period. The primary reason for the change iswas due to the conversionpurchase of $1.5 million of accounts receivable into a note receivablenew manufacturing and warehouse facility in Carlsbad, CA during the first quarter of fiscal 2018. This reduction2022.

Cash provided by financing activities for the three months ended September 30, 2022, was $2.8 million, compared to $10.0 million in the comparable prior year period. The difference is primarily due to a net withdrawal of $3.4 million on our credit facility in the three months ended September 30, 2022, whereas the three months ended September 30, 2021 had no corresponding credit facility withdrawal. The three months ended September 30, 2021 included borrowings related to the purchase of our new manufacturing and warehouse facility in Carlsbad, CA. The decrease in borrowings was partially offset by lower capital equipment purchasesan increase in repurchase of $2.1 million duringtreasury stock for the first half of fiscal 2018 asthree months ended September 30, 2022 compared to $3.3 million during the same six month period of fiscal 2017. Capital expenditures for both years were primarily for manufacturing equipment used in our Vista, California and Manno, Switzerland facilities.

18

Cash used in financing activities during the sixthree months ended December 31, 2017 primarily related to treasury shares returned to NAI by employees whose restricted stock vested during the quarter. In return NAI paid each employee's required tax withholding.September 30, 2021.  

 

We did not have any consolidated debt asAs of December 31, 2017 or JuneSeptember 30, 2017.

We have a Credit Agreement with Wells Fargo Bank, N.A.  The Credit Agreement provides us with a2022, we had $3.4 million outstanding on our credit line of up to $10.0facility and $16.6 million and matures on February 1, 2020. The line ofavailable for borrowing under our credit may be used to finance working capital requirements. On September 29, 2017, we executed an amendment to the Credit Agreement, that now allows us to make loans or advances to third parties in amounts not exceeding $1.5 million. We executed this amendment in order to issue a note receivable of $1.5 million to a customer. There is no commitment fee under this agreement. There are no amounts currently drawn under the line of credit.

Under the terms of the Credit Agreement, borrowings are subject to eligibility requirements including maintaining (i) a ratio of total liabilities to tangible net worth of not greater than 1.25 to 1.0 at any time; and (ii) a ratio of total current assets to total current liabilities of not less than 1.75 to 1.0 at each fiscal quarter end. Any amounts outstanding under the line of credit will bear interest at a fixed or fluctuating interest rate as elected by NAI from time to time; provided, however, that if the outstanding principal amount is less than $100,000 such amount shall bear interest at the then applicable fluctuating rate of interest. If elected, the fluctuating interest rate per annum would be equal to 1.25% above the daily one month LIBOR rate as in effect from time to time during the period loan amounts are outstanding. If a fixed interest rate is elected, the interest rate would equal a per annum rate of 1.25% above the LIBOR rate in effect on the first day of the term for which the fixed rate is elected. Any amounts outstanding under the line of credit must be paid in full on or before the maturity date. Amounts outstanding that are subject to a fluctuating interest rate may be prepaid at any time without penalty. Amounts outstanding that are subject to a fixed interest rate may be prepaid at any time in minimum amounts of $100,000, subject to a prepayment fee equal to the sum of the discounted monthly differences (calculated by comparing the fixed rate to the variable rate that would have been applied, had it been elected) for each month from the month of prepayment through the month in which the then applicable fixed rate term matures.

Our obligations under the Credit Agreement are secured by our accounts receivable and other rights to payment, general intangibles, inventory, equipment and fixtures. We also have a foreign exchange facility with Wells Fargo Bank, N.A. that is in effect until January 31, 2019, and a similar facility with Bank of America, N.A. that is in effect until August 15, 2019.

On December 31, 2017,Bank. During the three months ending September 30, 2022, we were in compliance with all of the financial and other covenants required under the Credit Agreement. Refer to Item 1, Note F., "Debt," in this Quarterly Report, for terms of our Credit Agreement.         

 

As of December 31, 2017,September 30, 2022, we had $28.8$9.7 million outstanding under the Term Note used in the purchase of the warehouse in August 2021.

As of September 30, 2022, we had $12.3 million in cash and cash equivalents and $10.0 million available under our credit facilities.equivalents. We believe our available working capital, cash, and cash equivalents, credit facility and potential cash flows from operations will be sufficient to fund our current working capital needs, and capital expenditures, and minimum debt and interest payments through at least the next 12 months. Our capital requirements for fiscal 2023 include amounts that will be required to complete our planned retrofit of the facility we purchased in August 2021 that is planned to become a powder blending, packaging, and storage facility.

 

Off-Balance Sheet Arrangements

 

As of December 31, 2017,September 30, 2022, we did not have any off-balance sheet debt nor did we have any transactions, arrangements, obligations (including contingent obligations) or other relationships with any unconsolidated entities or other persons that have or are reasonably likely to have a material current or future adverse effect on our financial condition, changes in financial condition, results of operations, liquidity, capital expenditures, capital resources, or significant components of revenue or expenses that are or could be material to investors.

 

Recent Accounting Pronouncements

 

Recent accounting pronouncements are discussed in the notes to our consolidated financial statements included under Item 1, Note A. of this Quarterly Report. Other than those pronouncements, we are not aware of any other pronouncements that materially affect our financial position or results of operations.

 

21

ITEM 4.    CONTROLS AND PROCEDURES

 

We maintain certain disclosure controls and procedures that are prescribedas defined under the Securities Exchange Act of 1934. These controls and proceduresThey are designed to help ensure that material information is: (1) gathered and communicated to our management, including our principal executive and financial officers, in a manner that allows for timely decisions regarding required disclosures; and (2) recorded, processed, summarized, reported and filed with the SEC as required under the Securities Exchange Act of 1934 and within the time periods specified by the SEC.

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (principal financial and accounting officer), evaluated the effectiveness of the design and operation of our disclosure controls and proceduresprocedures as of December 31, 2017.September 30, 2022. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that as of December 31, 2017 our disclosure controls and procedures were effective for their intended purpose described above.above as of September 30, 2022.

 

There were no changes toin our internal controlscontrol over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarterly period ended December 31, 2017September 30, 2022 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

 

1922

 

PART II - OTHER INFORMATION

 

ITEM 1.LEGAL PROCEEDINGS

 

From time to time, we become involved in various investigations, claims and legal proceedings that arise in the ordinary course of our business. These matters may relate to intellectual property, product liability, employment, tax, regulation, contract or other matters. The resolution of these matters as they arise will be subject to various uncertainties and, even if such claims are without merit, could result in the expenditure of significant financial and managerial resources by us.resources. While unfavorable outcomes are possible, based on available information, we generallycurrently do not believe the resolution of these matters, even if unfavorable, will result in a material adverse effect on our business, consolidated financial condition, or results of operations. However, a settlement payment or unfavorable outcome could adversely impact our results of operations. Our evaluation of the likely impact of these actions could change in the future and we could have unfavorable outcomes we do not expect. An unexpected settlement expense or an unexpected unfavorable outcome of a matter could adversely impact our results of operations.

 

As of February 13, 2018, except as described below,November 9, 2022, neither NAI nor its subsidiaryNAIE were a party to any material pending legal proceeding nor was any of our property the subject of aany material pending legal proceeding. We are currently involved in several legal matters in the ordinary course of our business, each of which is related to enforcing our intellectual property rights. Some of these matters are summarized below.business. 

 

In 2011, NAI filed a lawsuit against Woodbolt Distribution, LLC, also known as Cellucor (“Woodbolt”), and both NAI and Woodbolt filed additional lawsuits and countersuits against each other. NAI and Woodbolt subsequently settled all of the lawsuits between them, but not before the United States Patent and Trademark Office (“USPTO”) at Woodbolt’s request rejected the claims of two NAI patents. The rulings rejecting the claims of two NAI patents were subsequently confirmed by the Patent Trial and Appeal Board (PTAB) at the USPTO. NAI filed Notices of Appeal with the U.S. Court of Appeals for the Federal Circuit requesting that certain findings of the PTAB's be reversed. No hearing date has been set by the Court. Both NAI patents rejected by the USPTO expired in August 2017.

On September 18, 2015, NAI filed a complaint against Creative Compounds, LLC, alleging various claims including (1) violation of Section 43 of the Lanham Act, (2) violation of California's Unfair Competition Law, (3) violation of California's False Advertising Law, (4) Trade Libel and Business Disparagement and (5) Intentional Interference with Prospective Economic Advantage. Subsequently, NAI and defendant resolved their disputes and entered into settlement and the case was dismissed.

On August 24, 2016, NAI filed a separate complaint against Creative Compounds, LLC, alleging infringement of U.S. patent 7,825,084. On October 5, 2016, Creative filed its answer and counterclaims. On January 19, 2017, NAI filed a Motion to Amend the Complaint, to add allegations of infringement of U.S. patents 5,965,596, 7,504,376, 8,993,610 and 8,470,865, and adding the following additional parties: Core Supplement Technology, Inc., Honey Badger LLC, and Myopharma, Inc. The Court granted NAI's motion. On May 2, 2017, the Court issued a revised scheduling order and set a trial date for July 31, 2018. On July 19, 2017, Creative filed a motion for judgment on the pleadings to dismiss the patent infringement claims with prejudice, On September 5, 2017, the Court granted Creative's motion, which was a non-final decision and subject to later appeal to the U.S. Court of Appeals for the Federal Circuit. NAI has stated it will appeal the District Court rulings. The remaining non-patent claims pending against other defendants were not affected. On October 16, 2017, defendant Core Supplement Technology, Inc., filed a Notification of Bankruptcy with the Court. On October 17, 2017, NAI and defendant Honey Badger LLC filed a voluntary stipulation of dismissal, which the Court granted on October 20, 2017. On October 31, 2017, NAI and defendant Myopharma, Inc. filed a voluntary stipulation of dismissal, which the Court granted on November 6, 2017.  On November 9, 2017, NAI and Creative Compounds filed a joint motion to dismiss, which the Court granted on November 20, 2017. On November 21, 2017, NAI and Core Supplement Technology, Inc. filed a joint motion to dismiss, which the Court granted on November 27, 2017.  On December 8, 2017, NAI filed a Notice of Appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patents asserted against the defendants.  NAI's deadline to submit its opening brief to the Federal Circuit is currently April 13, 2018.   No hearing date has been set.

On July 6, 2016, NAI filed a complaint against Allmax Nutrition, Inc. in U.S. District Court for the Southern District of California, alleging (1) infringement of U.S. patents 5,965,596, 6,172,098, 7,825,084 and RE 45,947, (2) violation of Section 32 of the Lanham Act, and (3) copyright infringement. On October 19, 2016, NAI filed an amended complaint adding HBS International Corp., Allmax's exclusive distributor, as a co-defendant and to add a civil conspiracy claim.  On May 2, 2017, the Court issued a scheduling order setting a trial date for July 31, 2018. On April 25, 2017, defendants filed a motion for judgment on the pleadings and a motion to dismiss as to NAI's trademark and patent infringement and civil conspiracy claims. On June 26, 2017, the Court granted Defendants’ motions, dismissing NAI's patent infringement claim with prejudice and dismissing the trademark and civil conspiracy claims without prejudice. NAI filed a Second Amended Complaint on July 10, 2017. On August 29, 2017, the Court denied NAI's motion to partially reconsider the dismissal of the patent infringement claim, which is a non-final decision and subject to later appeal to the U.S. Court of Appeals for the Federal Circuit. NAI has stated it will appeal the District Court rulings. On August 30, 2017, the Court denied Defendants' motion to dismiss NAI's trademark and conspiracy claims. On September 29, 2017, both defendants filed their amended answers. Defendant HBS International Corp. also asserted a counterclaim for tortious interference with contract. NAI filed its response to the asserted counterclaim on November 10, 2017. The parties subsequently engaged in settlement discussions.  On December 22, 2017, NAI and defendants filed a joint stipulation of dismissal of the remaining claims, which the Court granted on January 2, 2018.

20

On September 16, 2016, NAI filed a complaint against Hi-Tech Pharmaceuticals, Inc. d/b/a ALR Industries, APS Nutrition, Innovative Laboratories, Formutech Nutrition, LG Sciences and Sports 1 in U.S. District Court for the Southern District of California, alleging (1) infringement of U.S. patents 5,965,596, 7,825,084, 8,993,610 and RE 45,947, (2) violation of Section 32 of the Lanham Act and (3) breach of contract. On May 2, 2017, the Court issued a scheduling order setting a trial date for July 31, 2018. On July 10, 2017, Defendants filed a motion for judgment on the pleadings to dismiss the patent infringement claims with prejudice. On September 5, 2017, the Court granted Defendants' motion, which is a non-final decision and subject to later appeal to the U.S. Court of Appeals for the Federal Circuit. NAI has stated it will appeal the District Court rulings. The remaining non-patent claims pending against the Defendants were not affected. On September 28, 2017, in a separate matter not involving NAI, the United States of America filed a First Superseding Criminal Indictment against defendants Hi-Tech Pharmaceuticals, Inc and its Chief Executive Officer, Jared Wheat. United States v. Hi-Tech Pharmaceuticals, et al., No.1:17-CR-0229 (N.D. Ga. 2017). On or about October 4, 2017, items in the possession of Hi-Tech were seized pursuant to a search warrant, including the documentation relevant to this case. In light of this development, the parties moved the Court on November 3, 2017, seeking an order staying all proceedings in the pending action until disposition of United States v. Hi-Tech Pharmaceuticals, et al., 1:17-CR-00229 (N.D. Ga 2017), or at a minimum, until the documents relevant to this case can be retrieved by the defendants. The Court granted the parties' motion to stay on November 9, 2017.  The case remains stayed as of this date.

Although we believe our claims in the above litigation matters are valid, thereThere is no assurance we will prevail in these litigation matters or in similar proceedings we or others may initiate or that our litigation expenses will not be greater than anticipated.

 

ITEM 1A.RISK FACTORS

 

When evaluating our business and future prospects you should carefully consider the risks describeddescribed under Item 1A of our 20172022 Annual Report, as well as the other information in our 20172022 Annual Report, this Quarterly Report and other reports and documents we file with the SEC. If any of the identified risks actually occur, our business, financial condition and results of operations could be materially adversely affected.seriously harmed. In that event, the market price of our common stock could decline, and you could lose all or a portion of the value of your investment in our common stock.

21

 

ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

We did not sell any unregistered equity securities during the three month periods ended September 30, 2022 and September 30, 2021.

 

Repurchases

 

During the quarter three months ended December 31, 2017,September 30, 2022 we did not sell any unregistered equity securities and we did not repurchase anyrepurchased 46,795 shares of our common stock under our stockat a total cost of $497,000 (including commissions and transaction fees) as set forth below:

Period

 

Total Number

of

Shares

Purchased

  

Average Price

Paid per Share

(1)

  

Total Number of Shares

Purchased as Part of

Publicly Announced

Plans or Programs

  

Maximum Number (or

Approximate Dollar Value) of

Shares that May Yet Be

Purchased

Under the Plans or Programs (as

of

September 30, 2022)

(in thousands)

 

July 1, 2022 to July 31, 2022

  11,777  $10.21   11,777    

August 1, 2022 to August 31, 2022

  21,143  $10.93   21,143    

September 1, 2022 to September 30, 2022

  13,875  $10.50   13.875    

Total

  46,795       46,795  $512 

(1) Average price paid per share includes costs associated with the repurchases

Refer to Note J, "Treasury Stock," in this Quarterly Report, for terms of repurchase plan.plan and additional information.

 

ITEM 3.DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 5.OTHER INFORMATION

 

None.

 

2223

 

ITEM 6. EXHIBITS

 

The following exhibit index shows those exhibits filed with this Quarterly Report and those incorporated by reference:

 

EXHIBIT INDEX

Exhibit

Number

Description

Incorporated By Reference To

3(i)

Amended and Restated Certificate of Incorporation of Natural Alternatives International, Inc. filed with the Delaware Secretary of State on January 14, 2005

Exhibit 3(i) of NAI’s Quarterly Report on Form 10-Q for the quarterly period ended December 31,September 30, 2004, filed with the commission on February 14, 2005

3(ii)

Amended and Restated By-laws of Natural Alternatives International, Inc. dated as of February 9, 2009

Exhibit 3(ii) of NAI’s Current Report on Form 8-K dated February 9, 2009, filed with the commission on February 13, 2009

4(i)

Form of NAI’sNAI’s Common Stock Certificate

Exhibit 4(i) of NAI’s Annual Report on Form 10-K for the fiscal year ended June 30, 2005, filed with the commission on SeptemberDecember 8, 2005

31.1

Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer

Filed herewith

31.2

Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer

Filed herewith

32

Section 1350 Certification

Filed herewith

101.INS

Inline XBRL Instance Document

Filed herewith

101.SCH

101.INS

Inline XBRL InstanceTaxonomy Extension Schema Document

Filed herewith

101.SCH

XBRL Taxonomy Extension Schema Document

Filed herewith

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

Filed herewith

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

Filed herewith

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

Filed herewith

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

Filed herewith

104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)Filed herewith

 

2324

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Natural Alternatives International, Inc., the registrant, has duly caused this Quarterly Report to be signed on its behalf by the undersigned, duly authorized officers.

 

 

Date: February 13, 2018November 9, 2022

 

 

NATURAL ALTERNATIVES

INTERNATIONAL, INC.

By:

/s/ Mark A. LeDoux

Mark A. LeDoux, Chief Executive Officer

 (principal(principal executive officer)

By:

/s/ Michael E. Fortin

Michael E. Fortin, Chief Financial Officer

 (principal(principal financial and accounting officer)

 

24

25